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ABSTRACT 
Neurodegeneration is the loss of neuronal structures or functions, while 
neuroprotection is the delay or prevention of neurodegeneration. In traumatic brain 
injury (TBI), neurodegeneration can occur as the result of oxidative stress, the imbalance 
of oxidants and antioxidants levels; therefore, antioxidant approaches can be effective 
therapeutic methods for neuroprotection by attenuating oxidative stress. Glutathione 
(GSH), a naturally occurring antioxidant, plays an important role in the maintenance of 
intracellular redox homeostasis by scavenging reactive oxygen species (ROS) and 
reactive nitrogen species (RNS). In this thesis, we attempted to evaluate the abilities of a 
GSH precursor, gamma-glutamylcysteine ethyl ester (GCEE), to prevent 
neurodegeneration by combating intracellular oxidative stress in neurons and 
astrocytes. For in vivo experiments, controlled cortical impact (CCI) was performed on 
Wistar rats to simulate moderate TBI, and GCEE (150 mg/kg) or saline was administrated 
30 min or 60 min after the brain injury. Fluoro Jade-B (FJB), an ionic fluorescein derivate, 
was adapted to selectively stain the degenerating neurons on the brain tissues, and FJB-
positive neurons were quantified. Administration of GCEE (150 mg/kg) post- injury 
decreased the number of FJB positive neurons that were significantly increased in saline 
treated groups. Next, the protective roles of GCEE in vitro in rat primary cortical 
astrocytes were investigated using various concentrations of tert-butyl hydroperoxide 
(tBHP) in order to induce oxidative stress and further toxicity. Cell viability was 
measured by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay. 
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The status of oxidative stress was determined by measuring intracellular ROS levels 
through dichlorofluorescein (DCF) assay. GCEE restored cell viability that was 
significantly decreased in untreated cells by decreasing oxidative stress. Lastly, the 
antioxidant properties of GCEE in neurons and astrocytes were investigated in a time-
dependent manner. GCEE was able to immediately attenuate intracellular oxidative 
stress both in neurons and astrocytes. Such decreased oxidative stress was progressively 
increased in neurons, whereas decreased oxidative stress remained in astrocytes. 
Overall, our current findings suggest the protective roles of GCEE in both neurons and 
astrocytes may contribute to the potential therapeutic effects on oxidative stress-
associated neurodegeneration following traumatic brain injury. 
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CHAPTER 1 
INTRODUCTION 
 
The brain is composed of two main types of cells: neurons and glia. Glia is further 
divided into astrocytes, oligodendrocytes, and microglia. The concentrations and 
distributions of cells are different depending on the regions of the brain and the types of 
the cells. Moreover, the functions of each cell are varied. Neurons have the ability to 
sense changes in environment, communicate with surrounding neurons, and respond to 
these changes due to their unique structure. Neurons contain axons and synapses which 
help transport and release chemical neurotransmitters (Fig.1.1). Neurons are the main 
cells contributing to the special functions of the brain, such as memory, learning, 
emotions, and perception. Neuronal damage can alter these functions and ultimately 
lead to overall brain dysfunction in these aforementioned areas. Glial cells fill the space 
between neurons regulate extracellular space and protect neurons. In particular, 
astrocytes play an important role in regulating glutamate concentrations to prevent 
glutamate neurotoxicity because glutamate is toxic at high concentrations and initiates 
glutamate-neurotoxicity although it is an essential excitatory neurotransmitter at 
normal concentrations. Another crucial role of astrocytes is supplying glutathione 
precursors in the extracellular space so that neurons can utilize them for glutathione 
synthesis, which ultimately protects neurons against oxidative stress (Dringen 2000). 
Additionally, astrocytes are involved in synaptogenesis and synaptic plasticity by 
releasing growth factors and neuromodulators (Ullian et al. 2004, Allen and Barres 2005, 
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Hu et al. 2007). Astrocytes also rapidly remove debris in the extracellular space. Thus, it 
is important to protect not only neurons, but also astrocytes because they interact with 
each other.  
 
 
Fig.1.1 Illustration of the interaction between neurons and astrocytes 
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Traumatic brain injury (TBI) is a serious health problem in all age groups. It is 
caused by a spontaneous, sudden accident. Once an accident occurs, the brain sustains 
primary physical damage, which can alter biochemical and cellular pathways. Primary 
injury then initiates acute or delayed secondary injury in which neuronal structures and 
functions are progressively altered. Accumulation of degenerating neurons is a pathway 
of neurological disorders. This entire process can be short term, occurring in hours to 
days, or long term, occurring in months to years. Therefore, development of therapeutic 
strategies to stop delayed secondary injury is necessary to prevent neurodegeneration 
and further neurodegenerative disorders.   
A large number of studies have investigated pathological consequences of 
traumatic brain injury at cellular and molecular levels to develop methods for 
neuroprotection. More specifically, the energy generated by the mechanical impact 
during the brain injury is immediately delivered to the brain tissue and the 
depolarization of neurons is subsequently induced, which causes an uncontrolled 
release of glutamate in the synaptic gap (Andriessen, Jacobs, and Vos 2010). The 
excessive amounts of glutamate bind to glutamate receptors on the membrane and 
consequently activate Ca2+ ion channels, thereby a massive influx of Ca2+ into neuronal 
cells occurs (Choi et al. 2012, Choi 1985, Choi, Koh, and Peters 1988). As a result, several 
pathophysiological processes are initiated within cell, and reactive oxygen species (ROS) 
and reactive nitrogen species (RNS) are subsequently overproduced in response to rapid 
elevation of extracellular glutamate and subsequently intracellular Ca2+ (Bullock et al. 
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1998, Choi 1985). In early experimental TBI models, significantly increased superoxide 
(•O2) and hydroxyl radicals (•OH) have been found as early as 5 minutes after TBI and 
lasted for few hours (Kontos and Povlishock 1986, Kontos and Wei 1986, Hall, Andrus, 
and Yonkers 1993). Nitric oxide synthase, an enzyme generating nitric oxide (•NO), has 
been shown to be activated in response to glutamate neurotoxicity following TBI, 
increasing levels of •ON; however, delayed overexpression of nitric oxide synthase has 
been observed (Griffith and Stuehr 1995, Orihara et al. 2001). Moreover, •ON reacts 
with •O2 and generates the toxic species peroxynitrite (ONOO-).  Peroxynitrite then 
undergoes further reactions, producing highly cytotoxic free radicals, including nitrite 
(•NO2), carbonate (•CO3), and •OH. Such dramatically increased levels of reactive 
oxidants exceed the capacity of the endogenous antioxidant defense system, and 
thereby ROS/RNS cannot be immediately removed, but instead are left inside the cell. 
Oxidative stress is implicated in the imbalance between ROS/RNS levels and 
antioxidants levels due to either overproduction of ROS/RNS or the depletion of 
antioxidants or both, resulting in the interruption of redox homeostasis, which can have 
long lasting effects on overall brain function and energy metabolism because highly 
reactive radicals rapidly react with cellular components, such as lipids, proteins, and 
DNA (Awasthi et al. 1997, Freire 2012). Subsequently, cellular components change their 
structure and function, ultimately leading to cellular death. Especially, peroxynitrite 
which interacts with proteins and lipids and increases levels of protein carbonyls, 3-
nitrotyrosine (3-NT), and 4-hydroxynonenal (4-HNE), as the markers of protein 
oxidation, protein nitration and lipid peroxidation, respectively (Hall et al. 2004, Reed et 
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al. 2009). Also, peroxynitrite reacts with mitochondria and oxidatively damage the 
membrane (Radi 1998). All this deleterious oxidative damage on the cellular 
components contributes to cellular death.   
Although pathological consequences of traumatic brain injury have been 
elucidated by a great amount of studies, a promising therapeutic agent is not available 
yet due to its complexity and heterogeneity. However, an increasing number of studies 
have shown that antioxidant approaches effectively prevent neurodegeneration by 
protecting neurons against oxidative stress as oxidative stress has been suggested as a 
major underlying cause of almost all neurodegenerative diseases. In particular, 
glutathione is the most abundant thiol (-SH) containing antioxidant in the brain. The 
essential role of glutathione is to maintain redox status within the cells by scavenging 
toxic reactive oxidants. Since a dramatic elevation of reactive oxygen and nitrogen 
species levels has been well characterized as a consequence of traumatic brain injury, 
promoting glutathione levels has been suggested as an effective neuroprotective 
strategy by effectively attenuating oxidative stress due to the ability of glutathione to 
eliminate ROS/RNS; however, the concentration of glutathione is limited due to both 
the limited availability of substrates and the regulation of biosynthesis by feedback 
inhibition (Richman and Meister 1975). Thus, administration of chemical substances that 
can increase intracellular glutathione has been suggested since glutathione itself is not 
effective because it is degraded into amino acids before it reaches the brain and it 
cannot easily cross the blood brain barrier (BBB) (Meister and Anderson 1983).  
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Gamma-glutamylcysteine ethyl ester (GCEE), an analogue of gamma-
glutamylcysteine (γ-GluCys) is a substrate for glutathione synthesis, has been shown to 
up-regulate total brain glutathione levels by overcoming feedback inhibition as well as 
mitochondrial glutathione (Drake et al. 2002, Drake et al. 2003). Up-regulated 
glutathione by GCEE has shown antioxidant capabilities to combat oxidative stress and 
decrease the makers of oxidative damage (Boyd-Kimball, Sultana, Poon, et al. 2005, 
Joshi et al. 2007) Since oxidative stress is one of the major causes of neurodegeneration 
in traumatic brain injury, we hypothesized that treatment with GCEE could combat 
increased reactive oxygen and nitrogen levels by boosting cellular glutathione levels in 
the brain, which may attenuate oxidative stress and damage, and ultimately preventing 
neurodegeneration (Fig.1.2).   
 
Fig.1.2 Schematic representation of hypothesis in this thesis 
GCEE 
Up-regulation of cellular GSH
Elimination of excessive ROS/RNS 
Attenuation of oxidative stress and damage
Neuroprotection
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The overall aim of my work was to investigate the neuroprotective effects of 
GCEE as a potential therapeutic agent in moderate traumatic brain injury. The first study 
(Chapter 3) was conducted to determine if administration of GCEE post-injury decreased 
the number of degenerating neurons in experimental TBI rat brain due to its ability to 
increase glutathione and attenuate oxidative stress in neurons. The second study 
(Chapter 4) was performed in rat primary cortical astrocytes in order to see whether 
GCEE could enter astrocytes and protect these structures against oxidative stress and 
oxidative stress-induced cytotoxicity. My final experiment (Chapter 5) was performed in 
rat primary cortical astrocytes and neuronal culture separately in order to assess any 
time course effects of GCEE in different cells types.  
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CHAPTER 2 
BACKGROUND 
2.1 Traumatic Brain Injury 
2.1.1 Overview 
According to the National Center for Injury Prevention and Control at the 
Centers for Disease Control and Prevention (CDC), approximately 2.5 million people in 
the United States reported emergency department visits, hospitalizations, or deaths due 
to traumatic brain injury in 2010, involving 2.2 million emergency department visits, 
280,000 hospitalizations, and 50,000 deaths. Unpredictable suddent accidents, such as 
falls (40.5%), hits by/against (15.5 %), motor vehicle crashes (14.3%), and assaults 
(10.7%), or unknown causes (19.0%) mainly contribute to traumatic brain injury 
according to the CDC. Traumatic brain injury is also a serious health concern  for military 
soldiers and athletes. In the military population, blast explosions are one of the main 
risk factors that cause TBI, especially for those who are deployed in combat regions 
(Rosenfeld et al. 2013). Athletes who are involved in sports, such as contact-collisions 
sports (i.e. boxing, football, ice hockey, rugby) and high-velocity sports (i.e skiing and 
motor racing), are more frequently and repeatedly exposed to TBI (Jordan 2013).  
2.1.2 Classification   
The Glasgow Coma Scale (GCS) classifies traumatic brain injury severity into 
three classifications: mild, moderate, and severe by measuring the level of 
consciousness. Scores range from 1 to 15: mild (GCS 13-15), moderate (GCS 9-12), and 
9 
 
severe (GCS ≤8) (Teasdale and Jennett 1974). The majority of TBI incidents are 
characterized as mild TBI (80%), and the rest are either considered moderate TBI (10%) 
or severe TBI (10%). There is a strong correlation between TBI severity and the risk of 
death.  Approximately 1 % of mild TBI, 15 % of moderate TBI, and 40 % of severe TBI die 
as a result of their brain injury (Andriessen, Jacobs, and Vos 2010, af Geijerstam and 
Britton 2003, Boto et al. 2009).   
Depending on the distribution of the damage produced by collision forces on the 
brain, TBI can be classified as focal or diffuse. Focal injury is limited to the site of impact 
or the opposite site of the impact, whereas diffuse injury involves extensive and 
widespread damage including axonal injury, or both focal and diffuse injuries may occur 
together (Andriessen, Jacobs, and Vos 2010). The location and severity of impact to the 
brain is related to neurological pathologies following TBI.  
Depending on the point of onset of the injury, TBI is characterized into two 
types: primary injury and secondary injury. The damage that occurs immediately by 
initial external physical impact is defined as a primary injury, while those initiated by 
primary injury are defined as secondary damage. Once TBI occurs, there is no way to 
reverse the primary injury, which indicates there is an increased risk  for secondary 
injuries to occur following TBI, which could take as little as a few hours to days or 
months to years (Zaloshnja et al. 2008). In other words, although people can survive 
from a traumatic brain injury and not show any immediate symptoms, long-term 
disabilities can arise due to delayed secondary injuries and reduce their quality of life.  
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2.1.3 Pre and post injury treatment 
Pre-injury treatment is related to preventative measures, using safety devices, 
such as helmets, seatbelts, and airbags. In contrast, post-injury treatment is related to 
providing therapeutic treatments after injury occurs to prevent delayed secondary 
injuries. Pre-injury treatment could reduce TBI severity as well as primary injury on the 
brain; however, pre-injury treatment itself cannot prevent the accidents from occurring. 
Once an accident happens, there is no way to reverse primary damage regardless of the 
severity of TBI. Thus, post-treatment strategy is a more effective approach and essential 
to preventing secondary injury.  
Application of hypothermia has been widely used in TBI patients as a post 
therapeutic option for neuroprotection; however, the effectiveness of this strategy is 
controversial to whether outcomes are improved or not (Sydenham, Roberts, and 
Alderson 2009, Urbano and Oddo 2012, Crossley et al. 2014). Although the necessity 
and importance of early post-TBI treatment are obvious, there are no known promising 
therapeutic strategies due to the complex and heterogeneous consequences. Thus, a 
plethora of studies have tried to elucidate the pathological processes following 
traumatic brain injury and develop strategies to prevent secondary injuries, including 
oxidative stress which accounts for neurodegeneration following TBI.    
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2.2 Reactive Oxygen Species and Reactive Nitrogen Species  
2.2.1 Overview 
Reactive oxygen species and reactive nitrogen species (ROS/RNS) are produced 
from normal biochemical processes in very small amounts. These toxic species are 
classified into radicals and non-radicals based on the presence of un-paired electron(s) 
on the outermost shell. Free radicals, such as superoxide (•O2), hydroxyl radical (•OH), 
nitric oxide (•NO), carbonate radical (•CO3), and nitrite radical (•NO2), have un-paired 
electron(s), while non-radicals, such as hydrogen peroxide (H2O2) and peroxynitrite (PN: 
ONOO-), do not have un-paired electron(s) (Table 2.1). Free radicals are highly reactive 
due to un-paired electrons and readily react with adjacent molecules to form stable 
electron pairs. Although non-radicals do not have un-paired electrons, they are still 
reactive because toxic free radicals are derived from non-radicals through several 
reaction processes, such as the Fenton reaction and the decomposition of peroxynitrite.  
The cells have an endogenous defense system against ROS/RNS, which either 
prevents ROS/RNS formation or eliminates existing ROS/RNS, thereby the 
concentrations of ROS/RNS are maintained below cytotoxic levels during normal 
physiological conditions. The endogenous defense system includes enzymes and low-
molecular weight antioxidants. Superoxide dismutase (SOD), catalase, and glutathione 
peroxidase (GPx) are the main protective enzymes, while glutathione is categorized as 
an antioxidant molecule.  
 
12 
 
Table 2.1 Reactive oxygen species and reactive nitrogen species                                             
 ROS/RNS Symbols Source 
Free 
radicals 
Superoxide •O2 Mitochondrial leakage 
hydroxyl radical •OH Fenton reaction  
nitric oxide •NO Nitric oxide synthase (NOS) 
carbonate radical •CO3 Decomposition of peroxynitrite 
Nitrite •NO2 Decomposition of peroxynitrite 
Non- 
radicals 
hydrogen peroxide H2O2 Superoxide dismutase 
peroxynitrite ONOO- The reaction of •O2 and •NO 
Source: Hall, E. D., R. A. Vaishnav, and A. G. Mustafa. 2010. “Antioxidant therapies for 
traumatic brain injury.” Neurotherapeutics 7 (1):51-61 
 
2.2.2 Superoxide 
Superoxide (•O2) is produced by reducing one molecule of oxygen (O2) with a 
single electron (Fig.2.1). During normal biochemical processes, 1-2% of total oxygen 
consumed by mitochondria is reduced to •O2 in the electron transport chain (ETC) on 
the mitochondrial membrane (Boveris 1977, Drose and Brandt 2012, Kowaltowski and 
Vercesi 1999). 
O2+ e
-  
NAD(P)H oxidase
→            •O2 
Fig.2.1 Formation of superoxide radical  
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2.2.3 Hydrogen peroxide 
Although •O2 is highly reactive, the chances of oxidative damage by •O2 itself are 
low because its activity with cellular components is relatively weak in aqueous 
conditions (Hall, Vaishnav, and Mustafa 2010). Moreover, once •O2 is formed, 
superoxide dismutase (SOD), immediately converts the free radical to hydrogen 
peroxide (H2O2) which is less reactive (Fig.2.2, step 1). 
Moreover, H2O2 is eliminated by either catalase or glutathione. Catalase reacts 
with two molecules of H2O2, producing two molecules of water (H2O) and O2 (Fig.2.2, 
step 2). Two molecules of glutathione scavenge one molecule of H2O2, generating two 
molecules of water and oxidized form of glutathione (GSSG), which is catalyzed by GPx 
(Fig.2.2, step 3).  
2(•O2) + 2H
+  
Superoxide dismutase (SOD)
→                  H2O2 + O2   (step 1) 
 
2H2O2  
Catalase
→     2H2O + O2   (step 2) 
 
H2O2+ 2GSH
Glutathione Peroxidase (GPx)
→                   2H2O + GSSG   (step 3) 
Fig.2.2 Formation and elimination of hydrogen peroxide 
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2.2.4 Hydroxyl radical 
Although H2O2 is less reactive and cytotoxic, the hydroxyl radical (•OH), the most 
toxic oxidizing agent due to its ability to react with almost every biological molecule 
found in the cells, is generated from H2O2 through the Fenton reaction in which ferrous 
iron (Fe2+) is oxidized into ferric iron (Fe3+) (Fig.2.3, step 1) (Rodopulo 1951, Haber and 
Weiss 1934). Ferric iron can be reduced back to ferrous iron by superoxide and ferrous 
iron then can be reused for another Fenton reaction (Fig.2.3, step 2). During normal 
physiological conditions, iron containing proteins, such as transferritin, ferritin, and 
hemoglobin, store iron with a high affinity at neutral pH so that iron concentrations can 
be maintained with non-toxic levels. However, when the pH is lowered by external 
impact on the cell during injury, the affinity of iron containing proteins towards iron is 
reduced, thereby excessive iron are released, leading to the overproduction of •OH 
(Hall, Vaishnav, and Mustafa 2010, Bains and Hall 2012).  
 
H2O2+ Fe
2+→ •OH+ OH-+ Fe3+  (step 1)  
 
•O2+ Fe
3+→ O2+ Fe
2+ (step 2)  
Fig.2.3 Fenton reaction showing the hydroxyl radical formation and recycling of iron 
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2.2.5 Peroxynitrite 
Peroxynitrite (PN: ONOO-) is formed through the reaction between nitric oxide 
(•ON) and •O2 (Fig.2.4, step 1) (Beckman 1991, Wada et al. 1998). Furthermore, when 
PN is protonated it can produce peroxynitrous acid (ONOOH), which is then 
decomposed into nitrite radical (•NO2)  and •OH (Fig.2.4, step 2) (Beckman 1991). 
Another reaction of PN with carbon dioxide (CO2) produces nitrosoperoxocarbonate 
(ONOOCO2), which is decomposed to •NO2 and the carbonate radical (•CO3) (Fig.2.4, 
step 3) (Bains and Hall 2012). Although PN itself is not highly reactive due to the absence 
of an un-paired electron, its derivatives, including •OH, •NO2, and •CO3 are highly 
reactive and toxic. 
 
•O2+ •NO →ONOO
- (step 1) 
 
ONOO-+ H+→ONOOH → •NO2+ •OH (step 2) 
 
ONOO-+ CO2→ ONOOCO2 → •NO2+ •CO3
- (step 3) 
Fig.2.4 Formation and decomposition of peroxynitrite 
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2.3 Cellular and Molecular Processes Following TBI 
2.3.1 Overview 
Following traumatic brain injury, complex cellular and molecular processes 
immediately occur and ultimately lead to neurological disorders. Glutamate, an 
important neurotransmitter at normal levels, but a key factor for initiating 
pathophysiological processes at high concentrations, is significantly increased at 
extracellular space following TBI. In response to glutamate neurotoxicity, •O2 and •ON 
are overproduced inside cells and peroxynitrite is subsequently generated from the 
reaction of •O2 and •ON. Peroxynitrite then diffuses within cells and is decomposed to 
produce reactive •OH, •NO2, and •CO3. Once it is decomposed, •OH, •NO2, and •CO3 
readily react with biological molecules such as proteins and lipids, leading to deleterious 
oxidative damage on cellular components through lipid peroxidation (LP), protein 
nitration, and protein carbonylation (Hall et al. 2004). Consequently, cellular and 
mitochondrial membranes are disrupted and proteins are aggregated. All this oxidative 
damage is irreversible and can promote neurodegeneration.   
2.3.2 Overproduction of ROS/RNS  
The mitochondria begin to overproduce •O2 in response to the accumulation of 
intracellular Ca2+ following TBI (Kontos and Povlishock 1986, Kontos and Wei 1986). 
Mitochondria take intracellular Ca2+ into the matrix to modulate ionic homeostasis on 
cytoplasm, which alters the structure of the electron transport chain on the 
mitochondrial membrane, thereby the damaged ETC boosts the production of •O2 
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(Kowaltowski, Castilho, and Vercesi 1995). Thus, the electron transport chain becomes 
the main location where the majority of •O2 is generated after TBI. Besides the ETC on 
the mitochondrial membrane, a variety of other sources are also involved with the 
overproduction of •O2 during brain injuries, such as the arachidonic acid cascade via 
prostaglandin synthase and  5-lipoxygenase activity, enzymatic or autoxidation of 
biogenic amine neurotransmitters (i.e. dopamine, norepineprine, 5-hydroxytryptamine), 
mitochondrial leakage , xanthione oxidase activity, oxidation of extravasted hemoglobin, 
and delayed activation of microglia, infiltration of neutrophils, and macrophages (Hall, 
Vaishnav, and Mustafa 2010, Moochhala et al. 2005, Rubinek and Levy 1993).  
2.3.3 Lipid peroxidation  
The brain has a high concentration of lipids, especially polyunsaturated fatty 
acids. Unstable ROS/RNS can readily react with lipids and induce lipid peroxidation (LP) 
through three steps: initiation, propagation, and termination. In particular, •OH mainly 
initiates lipid peroxidation. Initiation starts when •OH withdraws a hydrogen atom from 
lipids, thereby •OH itself becomes H2O and lipids themselves form lipid radicals (•L). 
Since •L is also unstable, •L reacts with O2, which yields a lipid peroxyl radical (•LOO) 
(Fig 2.5, step 1). Following initiation, •LOO propagates a series of chain radical formation 
reactions.  Previously produced •LOO deprotonates adjacent lipids, generating another 
•LOO with formation of lipid hydroperoxide (LOOH). Propagation is continuously carried 
out until no more lipids are available or until •LOO is transformed into a stable molecule 
by reacting with another radical or an antioxidant.  
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Fig.2.5 Schematic representation of lipid peroxidation process 
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Elevated levels of •OH and •O2 have been observed in early TBI models (Hall, 
Andrus, and Yonkers 1993, Hall et al. 1994, Kontos and Wei 1986). Since the cellular 
membrane, mitochondrial membrane, and blood-brain barrier (BBB) are made of lipids 
or polyunsaturated fatty acids, the elevation of •OH or •O2 in the brain after TBI leads to 
disruption of those membranes and BBB in the rats (Smith et al. 1994). As a result of 
lipid peroxidation, reactive aldehydes, such as acrolein, malondialdehyde, and 4-
hydroxynonenal (4-HNE) are produced. These are frequently used as an indicator of lipid 
peroxidation in many experimental TBI models to measure of levels of oxidative stress 
or damage (Fig.2.6). 4-HNE can further react with proteins, resulting in conformation 
and functional changes of proteins. 
 
Fig.2.6 Structures for several common products of lipid peroxidation 
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2.3.4 Protein nitration  
The derivatives of peroxynitrite, such as •NO2 and •CO3, react with proteins and 
produce oxidation products. Some proteins are more susceptible to oxidative damage 
than other proteins due to specific functional groups in their amino acids. For example, 
hydroxyl-containing amino acids (tyrosine) and amine-containing amino acids (histidine, 
arginine, proline, and lysine) are targeted by ROS/RNS and undergo nitration and 
carbonylation, respectively. In particular, 3-nitrotyrosine (3-NT), the end product of the 
nitration of a tyrosine residue, has been widely used as an index of oxidative stress and 
protein oxidation (Fig.2.7). This irreversible oxidative modification of proteins lead to 
conformational changes, thereby proteins may be aggregated or unfolded, and 
ultimately loss of function.   
 
Fig.2.7 Structure of 3-nitrotyrosine, a product of protein nitration 
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2.4 Glutathione 
2.4.1 Overview  
Glutathione (γ-glutamylcysteinylglycine), a tripeptide, is composed of glutamate 
(Glu), cysteine (Cys), and glycine (Gly) (Fig.2.8). The γ-peptide linkage between Glu and 
Cys is not easily hydrolyzed comparing to α-peptide bonds frequently found between 
two amino acids, thereby the stability of glutathione is enhanced.  
 
Fig.2.8 Structure of glutathione 
Moreover, the thiol group (-SH) of Cys can be deprotonated and reacts with 
other chemical molecules, contributing to several important functions of glutathione in 
the brain. One of the most important functions of glutathione is to scavenge ROS/RNS 
as an antioxidant, especially H2O2. One molecule of H2O2 is reduced to one molecule of 
water while two molecules of GSH are oxidized to form one molecule of oxidized 
glutathione (GSSG) which is catalyzed by the enzyme, glutathione peroxidase (GPx). 
Besides H2O2, glutathione can react with hydroperoxides and ONOO- to remove them 
from the cell (Sies et al. 1972, Srivastava, Awasthi, and Beutler 1974, Radi et al. 1991). 
22 
 
The advantage of glutathione is that it can be recycled because GSSG can be easily 
reduced to two molecules of GSH through the glutathione reductase (GR) enzyme in the 
presence of NADPH and H+ (Fig.2.9).  
 
Fig.2.9 Schematic representation of intracellular glutathione recycling process  
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2.4.2 Synthesis 
Glutathione is naturally synthesized in the cytoplasm of most cells, including 
neurons and astrocytes, through a two-step process. The biosynthesis of glutathione 
involves two ATP-dependent enzymes, gamma-glutamylcysteine synthetase (GCS) and 
glutathione synthetase (GS) for each step (Fig.2.10). The first step is the formation of 
gamma-glutamylcysteine (γ-GluCys) through a γ-peptide linkage between Glu and Cys, 
which is catalyzed by GCS. Upon the formation of γ-GluCys, GS catalyzes the next step to 
generate the final product, glutathione by adding Gly to γ-GluCys which was produced 
from the previous step (Snoke, Yanari, and Bloch 1953). 
 
Fig.2.10 Schematic representation of intracellular glutathione synthesis 
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Two main factors regulate biosynthesis of glutathione. First, non-allosteric 
feedback inhibition prevents continuous synthesis of glutathione in which glutathione 
itself inhibits the first reaction that is catalyzed by GCS by competing for the Glu or/and 
Cys sites on GCS, thereby the formation of γ-GluCys is reduced and the levels of 
glutathione is subsequently decreased (Richman and Meister 1975). The availability of 
Cys is another factor effecting the biosynthesis of glutathione because the 
concentration of Cys is relatively less than those of Glu and Gly (Raps et al. 1989). Thus, 
Cys is the rate determining substrate, which makes Cys-involving first step be the rate 
determining step in glutathione synthesis. 
2.4.3 Metabolism 
Although glutathione is synthesized within the cells, it is also found in the 
extracellular space. Astrocytes, one type of glial cell, release intracellular glutathione 
into extracellular space, which ultimately supplies glutathione precursors to other cells 
in the brain, including neurons (Fig.2.11) (Sagara, Makino, and Bannai 1996). In 
particular, extracellular glutathione is cleaved into glutamate and cysteinylglycine by γ-
glutamyltranspeptidase (γ-GT), an enzyme found on the cellular membrane of the 
astrocytes (Hird and Springell 1954, Meister, Tate, and Griffith 1981). Cysteinylglycine is 
then taken up by neurons or further hydrolyzed into cysteine and glycine by 
aminopeptidase N (ApN) enzyme found on the cellular membrane on the neurons 
(Meister 1988). Neurons take up extracellular cysteine through the excitatory amino 
acid transporters and utilize to synthesize intracellular glutathione (Dringen, Pfeiffer, 
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and Hamprecht 1999, Wang and Cynader 2000). Astrocytes also reuse extracellular 
cysteine by accepting as cystine through the cystine/glutamate transporter and convert 
it to cysteine inside the cell (Meister 1995, Anderson 1998, Bender, Reichelt, and 
Norenberg 2000). Therefore, the stores of extracellular glutathione secreted by 
astrocytes are good sources for neurons to synthesis intracellular glutathione (Sagara, 
Miura, and Bannai 1993).  
                               
Fig.2.11 Schematic representation of glutathione recycling process. Glutamate (Glu), Cysteine 
(Cys), Glycine (Gly), γ-glutamylcysteine (γGluCys), glutathione (GSH), Cysteinylglycine (CysGly), γ-
glutamyltranspeptidase (γGT), aminopeptidase N (ApN) 
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2.4.4 Up-regulation of glutathione 
As an antioxidant, glutathione plays a critical role in protecting the brain against 
oxidative stress by maintaining redox homeostasis; however, the depletion of 
glutathione causes oxidative stress due to relatively high levels of ROS/RNS. Oxidative 
stress is a pathway of almost all neurological pathways in the brain. Hence, elevation of 
glutathione levels may attenuate oxidative stress and protect the cells against oxidative 
damage, thereby preventing cellular death. However, provision of glutathione itself is 
not up-regulating cellular glutathione levels, because glutathione is rapidly degraded in 
the gut and circulated before it reaches the target location; it also is not transported 
into cells. Therefore, several glutathione precursors have been investigated as an 
alternative way to boost cellular glutathione levels, including glutathione ethyl ester and 
N-Acetylcysteine which provide glutathione and cysteine, respectively. Although both 
can increase cellular glutathione levels, the amount is limited due to feedback inhibition. 
Thus, provision of γ-glutamylcysteine has been suggested as an alternative way to boost 
glutathione by avoiding feedback inhibition.   
2.4.4.1 Gamma-glutamylcysteine ethyl ester 
Gamma-glutamylcysteine ethyl ester (GCEE) is a modified form of γ-
glutamylcysteine with an ester moiety, which is de-esterified by intracellular cellular 
esterase (Fig.2.12). The addition of ethyl ester moiety to γ-glutamylcysteine facilitates 
transport of GCEE across BBB as well as the plasma membrane (Anderson and Meister 
1989, Anderson et al. 1985, Levy, Anderson, and Meister 1993). It has been shown that 
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administration of GCEE increases total brain GSH levels by circumventing feedback 
inhibition (Drake et al. 2002). 
 
Fig.2.12 Structure of γ-glutamylcysteine ethyl ester  
A large number of studies have demonstrated the antioxidant abilities of GSH 
up-regulated by GCEE to protect the brain against a variety of oxidative stress. More 
specifically, GCEE has been shown to protect hippocampal neurons against ONOO- 
induced damage, in part preventing the loss of mitochondrial functions by increasing 
mitochondrial GSH levels in vivo and in vitro (Drake et al. 2003). Neuronal GSH levels 
have been increased in vitro by GCEE, which in turn protects neurons against Aβ(1-42)-
induced cytotoxicity, such as protein oxidation, mitochondrial dysfunction, and 
fragmentation of DNA, by decreasing oxidative stress (Boyd-Kimball, Sultana, Abdul, et 
al. 2005). Oxidative stress induced by Aβ(1-42) has been documented as the key factor 
causing Alzheimer’s disease like symptoms were are decreased by administration of 
GCEE (Boyd-Kimball, Sultana, Poon, et al. 2005). The degeneration of dopaminergic 
neurons has been also prevented by GCEE in a model of Parkinson’s disease which is 
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characterized by the reduction of GSH levels in selected brain regions (Chinta et al. 
2006). 
GCEE also has demonstrated its protective capability against oxidative stress 
related side effects of adriamycin, a chemotherapeutic drug used for treating solid 
tumors (Joshi et al. 2007, Aluise et al. 2009). Kainic acid, an excitatory neurotoxic 
molecule, also has been known to generate oxidative stress in the brain by disrupting 
ion homeostasis and stimulating production of oxidants; however, GCEE reduces 
oxidative stress-associated neuronal death by increasing the levels of glutathione 
(Turunc, Kanit, and Yalcin 2010, Yalcin et al. 2010)    
Furthermore, the capability of GCEE as an antioxidant to attenuate oxidative 
stress in TBI has been investigated. Post-treatment with GCEE following TBI reduced 
levels of protein carbonyls, 3-nitrotyrosine, and nitrated proteins, all biomarkers of 
oxidative damage in TBI (Reed et al. 2009). Also, GCEE showed protective effects on 
cerebral endothelial cells in TBI models (Lok et al. 2011).       
2.5 Experimental Methods 
2.5.1 Controlled Cortical Impact 
Human TBI is a heterogeneous disease, involving physical, physiological, 
behavioral, emotional, and histopathological changes. Although all these changes 
observed in human TBI cannot be perfectly reproduced in animal models, studying in 
animal models is an essential step to elucidate pathophysiological processes occurring 
after TBI, in order to develop new therapeutic strategies and assess the efficacy of 
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potential pharmaceutical therapies. Several types of TBI animal models have been 
investigated, such as controlled cortical impact, fluid percussion, weight drop, inertial 
acceleration, blast, and so forth (O'Connor, Smyth, and Gilchrist 2011). Depending on 
the types of techniques, advantages and disadvantages are involved. In this thesis, 
controlled cortical impact (CCI) was used and will be discussed.   
Controlled cortical impact (CCI) has been widely used in a variety of brain injury 
models. CCI was initially developed to investigate experimental TBI on the midline brain 
in ferrets by Lighthall and later adapted in rats by Dixon (Lighthall 1988, Dixon et al. 
1991). This approach uses a pneumatic impactor consisting of a small-ball to directly 
contact and impact the exposed intact brain. CCI has several advantages over other 
techniques. 1) Cortical contusions that are most commonly observed in human TBI can 
be induced by lateral controlled cortical impact; 2) Neurological changes that contribute 
to secondary injuries and chronic diseases following TBI can be observed; and 3) The 
velocity of an impactor can be calibrated to produce deformations with various depths 
and volumes, which is related to the severity of injury, such as mild, moderate, and 
severe. The faster the velocity of the impactor, the deeper the deformation in the brain 
(Dixon et al. 1991).  
2.5.2 Fluoro-Jade B Staining 
Fluoro-Jade B (FJB) is a common technique used for histochemical studies in 
brain tissue due to its ability to selectively stain degenerating neurons, including cell 
bodies, dendrites, axons, and axonal terminals (Schmued, Albertson, and Slikker 1997). 
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FJB positive neurons are observed under a fluorescence microscope and appear bright 
green against a dark background. FBJ has been widely used in experimental TBI models 
to study neurodegeneration (Anderson et al. 2005).  
Fluoro-Jade (FJ) was originally developed prior to FJB by Schmued, showing 
advantages over other staining methods in terms of sensitivity and simplicity (Schmued, 
Albertson, and Slikker 1997). The results were reliable and easy to interpret. Later, FJB 
modified from FJ later shows greater affinity and contrast than FJ (Schmued and 
Hopkins 2000). FJB can be combined with other staining methods, such as 
immunofluorescence to detect activated glial cells, thereby the effects of activated glial 
on the degenerating neurons or vice versa can be investigated (Schmued, Albertson, and 
Slikker 1997).    
The exact mechanism of how FJB can selectively stain degenerating neurons and 
not healthy neurons is unclear. However, it is assumed that degenerating neurons may 
release strongly basic molecules, thereby highly acidic FJB could possibly bind to those 
basic molecules (Schmued, Albertson, and Slikker 1997). Three possible fluorescent 
compounds that are responsible for the ability of FJB to detect degenerating neurons 
were discovered (Xu et al. 2005). They are 1) 5-(6’-hydroxy-3’-oxo-3H-xanthen-9’-
yl)benzene-1,2H-tricarboxylic acid; 2) 2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-5-(2,4-
dihydroxybenzoyl)terephthalic acid; and  3) 4-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-6-(2,4-
dihydroxybenzoyl)isophthalic acid.  
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2.5.3 Tert-butyl hydroperoxide  
Tert-butyl hydroperoxide (tBHP) is an oxidizing agent, which is converted into 
hydroperoxides, such as t-butylperoxy radicals (t-BuOO•) and t-butox radicals (t-BtO•) 
by endogenous iron once it is transported into the cell (Cadenas and Sies 1982, Abe and 
Saito 1998). It has been widely used over H2O2 to induce oxidative stress and assess the 
roles of endogenous GSH or exogenous GSH in a variety of in vitro studies because 
addition of H2O2 makes it difficult to exclude the role of catalase in removing H2O2.  
Instead, tBHP destroys catalase, which allows it assess the roles of GSH because GSH can 
react with not only H2O2, but also organic hydroperoxides (Pichorner, Jessner, and 
Ebermann 1993, Sies et al. 1972, Awasthi et al. 1997). It has also been found that 
toxicity of tBHP can be attenuated by GPx with glutathione, but not by superoxide 
dismutase nor catalase (Abe and Saito 1998).  
2.5.4 MTT assay 
The MTT assay is a colorimetric assay for determining cell viability based on their 
ability to reduce MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) 
into formazan crystals (Fig2.13). Since the MTT assay was originally developed by 
Mossman to quantify survival cells, it has been successfully applied to the determination 
of cytotoxicity in compounds as well (Mosmann 1983). The body consists of a variety of 
cell types, and each cell type has a different resistance to the same compound. One 
specific cell type can show various viabilities to different types of compounds. Thus, the 
MTT assay is an essential step in in vitro studies for establishing the proper 
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concentrations of the compound of interest and incubation times before evaluating the 
efficacy of the potential therapies so that the results can be independent on the 
numbers of living cells. 
MTT is initially colorless and water soluble. Once it is reduced by mitochondrial 
esterase inside the cells, formazan crystal products, become intensely purple colored 
(Fig2.13). The concentrations of formazan are measured by a microplate absorbance 
reader. Since the number of active mitochondria is related to the number of living cells, 
the concentration of formazan is proportional to the number of viable cells. The 
disadvantage of MTT assay is that formazan is insoluble. Thus, dissolving formazan in 
dimethyl sulfoxide or some other solution is a crucial step, which has been suggested as 
the major technical problem because of the efficacy of solution. Despite this 
disadvantage, the results of the MTT assay are more sensitive and reliable than other 
similar staining techniques. 
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Fig.2.13 Reaction of MTT assay. Mitochondrial reductase in living cells reduces MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5- diphenyl tetrazolium bromide) and forms formazan. 
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2.5.5 DCF assay  
The DCF assay has been widely used as a fluorometric assay for measuring 
intracellular ROS/RNS formations (Wardman 2008). Since the DCF assay is based on the 
conversion of non-fluorescent to highly fluorescent substances, an increase in 
fluorescence is measured instead of a decrease in fluorescence, which can diminish 
estimations. Also, the DCF assay itself is very sensitive to changes in the redox state, 
easy to use, requires a small amount of sample, and is inexpensive.  
DCFDA (2’,7’-Dichlorofluorescein diacetate) was originally developed to quantify 
H2O2 and hydroperoxides in the cell (Keston and Brandt 1965, Brandt and Keston 1965). 
DCFDA, the non-fluorescent compound, is permeable to the cell membrane. Upon the 
influx of DCFDA into the cells, the two ester bonds of DCFDA are hydrolyzed by cellular 
esterase, producing non-fluorescent DCFH (Fig.2.14). Since DCFH is relatively polar and 
has poor permeability to cross the cell membrane, DCFH is not effused extracellularly, 
but instead is accumulated within the cells for a few hours. DCFH is then oxidized into 
fluorescent DCF by various ROS/RNS and oxidizing enzymes (Fig.2.14). For example, 
•OH, •NO, •NO2, and •CO3 non-enzymatically oxidize DCFH, while xanthine oxidase and 
hypoxanthine oxidase enzymatically oxidize DCFH (Zhu et al. 1994, Gunasekar et al. 
1995). Thus, the level of fluorescence measured by a fluorescence microplate reader at 
the end of a kinetic run of the assay is a useful indicator of not just ROS levels, but the 
overall oxidative stress state in the cells (Wang and Joseph 1999, LeBel, Ischiropoulos, 
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and Bondy 1992). In other words, the DCF assay can be applied to evaluate the efficacy 
of antioxidants against oxidative stress in the cells (Wang and Joseph 1999).        
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Fig.2.14 Reaction of DCF assay. Non fluorescent H2DCFDA (2’,7’-dichlorodihydrofluorescein 
diacetate) crosses the cellular membrane. H2DCFDA is then hydrolyzed into H2DCF (2’,7’-
dichlorodihydrofluorescein) by cellular esterase. H2DCF is then converted into fluorescent DCF 
(2’,7’-dichlorofluorescein) by ROS/RNS. 
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CHAPTER 3 
NEUROPROTECTIVE EFFECTS OF GAMMA-GLUTAMYLCYSTEINE ETHYL ESTER ON 
CONTROLLED CORTICAL IMPACT-INDUCED MODERATE TRAUMATIC BRAIN INJURY  
 
3.1 Overview 
Traumatic brain injury (TBI) is a risk factor for neurodegeneration. Oxidative 
stress is one of the underlying causes leading to neurodegeneration in TBI. Glutathione 
(GSH) is the most abundant endogenous antioxidant in the brain and plays an important 
role in preventing oxidative stress by scavenging reactive oxygen species (ROS) and 
reactive nitrogen species (RNS). Biosynthesis of glutathione is regulated by non-
allosteric feedback inhibition, thereby elevated ROS/RNS levels by TBI exceeds the 
capability of brain glutathione levels. Gamma-glutamylcysteine ethyl ester (GCEE) is a 
glutathione precursor. Administration of GCEE in vivo and in vitro has been shown to up-
regulate cellular glutathione levels in the brain by circumventing feedback inhibition, 
and up-regulated GSH decreases oxidative stress and oxidative damage. In this study, 
we investigated the protective role of GCEE against neurodegeneration in traumatic 
brain injury. Controlled cortical impact (CCI) was performed on male Wistar rats to 
simulate a moderate traumatic brain injury. Fluoro-Jade B (FJB) staining was adapted to 
detect degenerating neurons on brain tissue. The number of FJB-positive neurons was 
measured for quantitative analysis. Administration of GCEE post TBI by intraperitoneal 
(i.p) injection decreased the total number of FJB-positive neurons in the brain compared 
to untreated controls. These results suggest that GCEE protects neurons against 
oxidative stress-induced neurodegeneration in traumatic brain injury. The 
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neuroprotective efficacy of GCEE as a potential therapeutic agent may contribute to the 
prevention of delayed neurological pathologies in traumatic brain injury.  
3.2 Introduction 
Neurons are distributed throughout the brain and are responsible for unique 
functions of the brain. Neurodegeneration is the progressive loss of neuronal structures 
and functions, which is a pathway of almost all neurological disorders. In the brain, 
oxidative stress is one of the leading causes of neurodegeneration, attributing to many 
neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases (Lee et al. 
2010, Jomova et al. 2010). Traumatic brain injury is an unpredictable sudden accident, 
accompanying with irreversible damage to the brain. This phenomenon involves primary 
and secondary injuries. At the moment of an incident, the external physical impact on 
the brain initially generates primary injury, such as swelling and shearing of neurons as 
well as the changes in cellular and molecular pathways. Subsequently, primary injury 
initiates immediate or delayed secondary injury, including the breakdown of the blood 
brain barrier (BBB), the initiation of excitotoxicity, the accumulation of extracellular 
glutamate, the disruption of intracellular ion homeostasis, and the overproduction of 
toxic radicals, resulting in oxidative stress (Giza and Hovda 2001, Barkhoudarian, Hovda, 
and Giza 2011, Freire 2012).  
The brain has the ability to combat excess levels of reactive oxygen and nitrogen 
species, using glutathione, which is a tripeptide containing a thiol (-SH) group and highly 
abundant in brain. However, the depletion of glutathione has been well documented in 
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a variety of TBI models. Therefore, it is highly required to boost cellular glutathione 
levels post brain injury to protect neurons against oxidative stress and it has been 
shown that administration of GCEE up-regulates glutathione levels in the brain, 
including neuronal cells and neuronal mitochondria by avoiding feedback inhibition 
(Drake et al. 2002, Drake et al. 2003). Such up-regulated glutathione by GCEE has shown 
antioxidant ability to combat oxidative damage induced by a variety of oxidizing agents, 
including Aβ(1-42), adriamycin, MPTP, and ONOO- (Boyd-Kimball, Sultana, Abdul, et al. 
2005, Boyd-Kimball, Sultana, Poon, et al. 2005, Joshi et al. 2007, Chinta et al. 2006, 
Drake et al. 2002). Furthermore, the antioxidant properties of GCEE in TBI models have 
been shown by others (Reed et al. 2009, Lok et al. 2011).  
In this study, we investigated whether administration of GCEE post-traumatic 
brain injury in experimental rats could prevent neurodegeneration due to its antioxidant 
ability to decrease oxidative damage as a precursor of glutathione in the brain. For 
quantitative analysis, Fluoro-Jade B (FJB) was selected to stain degenerating neurons 
and changes in the number of degenerating neurons were measured (Schmued and 
Hopkins 2000).   
3.3 Materials and Procedures 
3.3.1 Chemicals and Materials  
All chemicals and gel-coated slides used for FJB staining were provided by Dr. 
Bardgett at Northern Kentucky University. GCEE was purchased from Bachem (Torrance, 
CA).  
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3.3.2 Animal Surgical Procedures and Treatments 
For this study, sixteen Wistar adult male rats (Harlan Laboratories, Indianapolis, 
IN, USA) were used whose average weight was approximately 215g. Animals were 
divided into three groups (Sham, Saline, GCEE). A naïve rat, in which no craniotomy, 
injury or treatment, was used as well. The sham group was treated as the control group, 
so neither injury was induced nor treatment was administrated; however, a craniotomy 
was performed. Both Saline and GCEE groups were subjected to a moderate TBI (1.5 
mm depth injury). Saline groups were treated with saline (150 mg/kg) instead of GCEE, 
while GCEE groups were treated given 150 mg/kg GCEE for treatment. Saline and GCEE 
groups were further divided into multiple groups (Saline 30, Saline 60, GCEE 30, and 
GCEE 60) depending on the time delay of treatment. Saline or GCEE was administrated 
either 30 min or 60 min after TBI was performed. Each group had three rats (n= 3) 
except the naïve group which had one rat. 
All rats (except for the naïve rat) were completely anesthetized with 3.0 % 
isoflurane and placed in a stereotaxic frame (David Kopf Instruments, Tujunga, CA). 
Surgery and injury were completed as previously described (Sullivan et al. 2002). First, a 
craniotomy was performed in which the hair on the scalp was shaved, the skin 
retracted, and the skull cap was gently removed. Controlled cortical impact (CCI) was 
then induced onto the exposed brain to produce cortical contusions by an impactor 
containing a metal ball which was calibrated to make a 1.5 mm deep deformation and 
simulate moderate TBI as previously described, except for sham groups (Sullivan et al. 
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2002). After craniotomy and surgery, a 4 mm disk made from dental cement was placed 
over the craniotomy site and adhered to the skull with cyanoacrylate. The skull cap was 
placed back and the skin was sutured. The rats were placed onto a heating pad until 
they regained consciousness and started to move normally. Saline or 150 mg/kg GCEE 
was administrated through i.p. injection 30 min or 60 min after CCI for non-treatment or 
treatment groups, respectively. The rats kept alive for 24 hour. For histochemical 
analysis, the rats were sacrificed after 24 hour by overdose of pentobartital and 
perfusion was performed. The whole brains were rapidly removed after decapitation 
and stored in 10% formalin until use. Depending on whether CCI was performed or not, 
the difference was observed on the surface of the brains. On the surface of all CCI-
induced brains cortical contusions appeared with red color regardless of the 
administration of GCEE or saline, whereas no cortical contusions were shown on the 
brain in naïve and sham groups (Fig.3.1). 
                             
Fig.3.1 Images of rat brains with CCI (left) and without CCI (right).  Cortical contusion was not 
produced when CCI was not performed, while a 1.5mm deep cortical contusion was produced 
when CCI was performed. The red color shows the injury site for CCI treated animals.  
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3.3.3 Tissue preparation 
To prepare brain tissues, each brain sample was completely frozen and sectioned 
into 40 microns thickness at -25°C, using a cryostat (Leica CM 1850). Every other brain 
section was collected into a 24-well plate containing 0.1M potassium phosphate buffer 
solution (KPBS) + 0.05% sodium azide. The sections were mounted on gelatin coated 
slides and dried overnight at room temperature for FJB staining.  
3.3.4 Fluoro-Jade B staining 
The slides were first immersed into a solution containing 100% ethanol for 3 min, 
next transferred into a solution containing 75% ethanol for 1 min, and then rinsed with 
distilled water for 1 min. The slides were then placed into a solution containing 0.06% 
potassium permanganate (KMnO4) for 15 min on a shaker and rinsed with distilled 
water for 1 min. The sections were stained with a solution containing 0.001% FJB 
(Histochem Inc., Jefferson, AR) for 30 min by gently shaking on a shaker in a dark room. 
The slides were washed with distilled water for 1 min three times and dried overnight at 
room temperature in a completely dark room. The slides were then immersed into 
100 % xylene for 2 min three times and coverslipped with DPX mounting media.        
3.3.5 Statistical Analysis  
Experiments were performed with three animals per group (n = 3) except naïve 
(n=1). All data were analyzed using ANOVA and expressed as mean ± SD. Statistical 
significance was set at p < 0.05.  
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3.4 Results 
3.4.1 Craniotomy injury causes neurodegeneration  
Craniotomy is the mandatory step before performing CCI, which may possibly 
affect neurons somehow because the brain is exposed to molecular oxygen while a 
small piece of skull is removed. Hence, craniotomy was also performed on control 
groups, including sham, but not naïve, although the skull was immediately placed back 
and the wound was sutured. The difference in the number of FJB-positive neurons was 
actually observed between sham and naïve groups. While FJB-positive neurons did not 
appear on the brain tissues of the naïve group, FJB-positive neurons were observed on 
the cortex of brain tissue in sham groups although CCI was not performed on sham 
groups (Fig.3.2). This result suggests that the craniotomy process itself can induce 
neurodegeneration without CCI. Thus, sham group was selected as control group over 
naïve group for following analysis.  
3.4.2 GCEE decreases neurodegeneration in controlled cortical impact-induced rats 
After craniotomy, CCI was performed to induce moderate TBI on GCEE and Saline 
treated groups. GCEE (150 mg/kg) was subsequently administrated 30 min or 60 min 
after CCI, while for non-treatment groups, saline was administrated 30min or 60 min 
after CCI. Prepared brain tissues were stained with FJB. The brain tissues obtained from 
non-treatment groups were more deformed compared to those of GCEE-treated groups. 
In addition, FJB-positive neurons were more widely distributed on the brain tissues in 
non-treatment groups compared to GCEE-treated groups (Fig.3.3). The effects of GCEE 
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on degenerating neurons were measured in different treatment groups by quantifying 
the number of fluorescent neurons stained by FJB. Injured groups had increased 
numbers of FBJ-positive neurons in the cortex compared to sham groups, whereas GCEE 
treated rats after brain injury decreased in the number of FJB-positive neurons than that 
of non-treated rats (Table 3.1).  
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Fig.3.2 Images of FJB stained cortex and hippocampus from naïve and sham. Cortex of naïve 
((1), (1A)), cortex of sham ((2), (2A)), hippocampus of naïve ((3), (3A)), and hippocampus of sham 
((4), (4A)). Images ((1), (2), (3), (4)) are captured at 2.5X magnification and images ((1A), (2A), 
(3A), (4A)) are captured at 10X magnification. Craniotomy-induced rats showed FBJ-positive 
neurons in the cortex.   
46 
 
 
Fig.3.3 Images of the brain tissues stained by FJB after CCI and treatments. Saline 30 (A), GCEE 
30 (B), Saline 60 (C), and GCEE 60 (D). Images are captured at 10X magnification.    
 
Table 3.1 Average number of degenerating neurons stained by FJB on rat brain tissues. GCEE 
(150 mg/kg) or saline was administrated to rats 30 min or 60 min after controlled cortical 
impact. The quantity of FJB positive neurons appeared on the images of the brain tissues 
captured at 2.5X magnification was measured within a rectangle 0.1 mm x 0.2 mm (n=3). Values 
are expressed as mean ± SD.  
 
 
 
 
 
Groups 
Average number of FJB-positive neurons  
(in 0.02 mm²) 
Sham 17 ± 21 
Saline 30 22 ± 7 
GCEE 30 18 ± 2 
Saline 60 27 ± 5 
GCEE 60 20 ± 5 
(C) (D) 
(B) (A) 
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3.5 Discussion 
Traumatic brain injury is a risk factor for neurodegeneration (Sato et al. 2001, 
Anderson et al. 2005, Hall et al. 2008, Hall et al. 2005). Neurodegeneration contributes 
to neurodegenerative disorders, such as Alzheimer’s diseases following TBI (Van Den 
Heuvel, Thornton, and Vink 2007, Sivanandam and Thakur 2012). Oxidative stress has 
been suggested as the underlying cause of neurodegeneration in TBI by overproducing 
reactive oxygen and nitrogen species (Awasthi et al. 1997, Tyurin et al. 2000, Kontos and 
Povlishock 1986). Administration of GCEE post-TBI increases brain glutathione levels and 
decreases the markers of oxidative damage (Lai et al. 2008, Reed et al. 2009). 
In the present study, the total number of degenerating neurons was higher in TBI 
rats compared to non-injury rats (Table 3.1), proving that TBI causes 
neurodegeneration. It also has been proven in a variety of experimental TBI models by 
histochemical studies although the concentrations, contributions, and time of 
appearance are different depending on the types of injury-inducing methods and 
severity of injury (Anderson et al. 2005). In the fluid percussion method, degenerating 
neurons are initially observed in cortex as early as 3 h post-TBI and the maximum 
numbers are measured 24 h after an injury in TRBI rats (Sato et al. 2001). In CCI induced-
TBI mice and rats, degenerating neurons are immediately seen in the ipsilateral cortex 
around the site of impact, and the number of degenerating neurons has a time 
dependent increase until 48 h post-injury (Hall et al. 2005, Hall et al. 2008). However, in 
our study, administration of GCEE after CCI decreased the number of degenerating 
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neurons compared to non-treatment rats, showing that treatment with GCEE post-TBI 
prevented neurodegeneration and early treatment was more effective. This could be 
due to the antioxidant role of gamma-glutamylcysteine ethyl ester in TBI as previously 
investigated in experimental TBI models by other groups. Administration of GCEE in CCI-
induced mice preserved total brain glutathione levels which were significantly 
decreased in non-treatment mice as well as markers of oxidative stress-induced 
autophagy were significantly decreased (Lai et al. 2008). Similarly, administration of 
GCEE in TBI rats significantly decreased the levels of 3-NT and 4-HNE which were 
increased in non-treatment groups as the markers of oxidative damage by peroxynitrite 
(Reed et al. 2009). Similarly, GCEE administration in CCI-induced mice decreased acute 
blood-brain barrier (BBB) permeability by protecting endothelial cells against oxidative 
stress (Lok et al. 2011). Taken together, the results from this study suggest that early 
treatment with GCEE post-TBI can protect neurons against oxidative stress-related 
degeneration in traumatic brain injury. Neurons contribute to the critical functions of 
the brain, including learning, memory, emotions, and perception. Thus, protecting 
neurons is important to prevent the subsequent neurological changes and pathologies.  
In conclusion, this study has shown that the GCEE’s antioxidant capabilities 
protect neurons against oxidative stress-related degeneration in TBI. This 
neuroprotective efficacy of GCEE may contribute to the prevention of delayed 
neurological disabilities in traumatic brain injury as a potential therapeutic agent.  
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CHAPTER 4 
GAMMA-GLUTAMYLCYSTEINE ETHYL ESTER PROTECTS ASTROCYTES AGAINST TERT-
BUTYL HYDROPEROXIDE MEDIATED-OXIDATIVE STRESS AND CYTOXICITY  
 
4.1 Overview 
Glutathione is a naturally occurring antioxidant in the brain. The capability of 
glutathione to scavenge intracellular reactive oxygen and nitrogen species protects the 
cells against oxidative damage during normal conditions. However, cells are susceptible 
to oxidative stress during brain injury because oxidants are immediately overproduced 
and the availability of glutathione is reduced. Hence, increasing the level of glutathione 
is essential to decrease oxidative stress and protect cells. Gamma-glutamylcysteine ethyl 
ester has been known to increase neuronal and mitochondrial glutathione in the brain 
as a precursor of glutathione. In this study, we investigated whether GCEE could up-
regulate glutathione in astrocytes specifically, and if such upregulation could attenuate 
oxidative stress in astrocytes and further protect astrocytes against oxidative stress-
induced cytotoxicity. Oxidative stress was induced to rat primary cortical astrocytes by 
adding an oxidizing agent, tert-butyl hydroperoxide. The status of oxidative stress was 
measured by adapting the dichlorofluorescein assay. Treatment of astrocytes with GCEE 
significantly reduced tBHP-induced oxidative stress. GCEE treatment also prevented a 
decrease in cell viability in a dose dependent manner. These results suggest that GCEE 
can protect astrocytes against oxidative stress-induced cytotoxicity, which may be due 
to its ability to increase glutathione. These beneficial effects of GCEE on astrocytes may 
contribute to its role as a neuroprotective agent in traumatic brain injury.  
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4.2 Introduction 
Overproduction of cellular reactive oxygen and nitrogen species depletes 
antioxidant levels. The imbalance between the levels of oxidants and antioxidants 
results in oxidative stress. Oxidative stress is accompanied with oxidative damage 
because unstable free radicals rapidly react with cellular components, such as cellular 
and mitochondrial membranes, proteins, and nucleic acids, which alter their 
conformations and functions. As a result, the permeability of the cellular membrane and 
BBB is increased, proteins are aggregated or unfolded, and DNA is mutated, which 
consequently contributes to cellular death.  
Astrocytes are the most abundant glial cells in the brain, outnumbering the 
neurons in the brain. The distribution of brain glutathione is uneven, but localized in 
non-neuronal cells (Slivka, Mytilineou, and Cohen 1987). In particular, much higher 
concentrations of intracellular glutathione has been found in astrocytes (3.8 mM) than 
in neurons (2.5mM) (Raps et al. 1989, Rice and Russo-Menna 1998). Thus, the majority 
of glutathione in the brain is related to astrocytes. In addition, the substrates required 
for biosynthesis of neuronal glutathione, such as cysteine, are supplied by astrocytes 
through the γ-glutamyl cycle in which astrocytes release intracellular glutathione into 
extracellular space (Walz 1989, Sagara, Makino, and Bannai 1996). Such released 
glutathione is cleaved into glutamate and the dipeptide, cysteinylglycine, by γ-glutamyl 
transpeptidase, an enzyme found on the membrane of astrocytes. Cysteinylglycine is 
subsequently cleaved into cysteine and glycine by aminopeptidase N, which is found on 
51 
 
plasma membrane of neurons (Meister, Tate, and Griffith 1981, Meister 1995). 
However, astrocytes are targeted to attacks of reactive oxygen and nitrogen species 
during traumatic brain injury. Subsequently, astrocytic glutathione levels are diminished 
and oxidative stress prompts cellular death through irreversible oxidative damage.  
In this study, we investigated whether GCEE could increase glutathione in 
astrocytes and protect astrocytes against oxidative stress as GSH precursor. Oxidative 
stress was induced in rat primary cortical astrocytes by adding tert-butyl hydroperoxide, 
an oxidizing agent. tBHP has been widely used as an oxidizing agent in various in vitro 
models because tBHP is stable and has a greater membrane permeability in astrocytes 
(Abe and Saito 1998). The levels of intracellular oxidative stress were measured by 
dichlorofluorescein assay which is based on the conversion of non-fluorescent 
compounds into fluorescent compounds through reaction of intracellular reactive 
oxygen and nitrogen species (Keston and Brandt 1965, Wang and Joseph 1999). The 
toxicity of substances and cell viabilities were measured by MTT assay based on the 
formation of formazan from MTT through the activation of mitochondrial cellular 
enzymes in living cells (Mosmann 1983).  
4.3 Materials and Methods 
4.3.1 Materials 
All reagents required for culturing astrocytes, such as Dulbecco’s Modified Eagle 
Medium (DMEM; high glucose), Fetal Bovine Serum (FBS), and Accutase were purchased 
from Invitrogen (Carlsbad, CA, USA). All reagents required for experiments, such as 
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Dulbecco’s Phosphate Buffered Saline (D-PBS; without Ca2+, Mg2+, and phenol red), 
Hank’s Balanced Salt Solution (HBSS), and MTT assay kit were also purchased from 
Invitrogen (Carlsbad, CA, USA). Both H2DCFDA (2,7-dichlorodihydrofluorescein 
diacetate) and tBHP (tert-butyl hydroperoxide) were purchased from Acros Organics. 
GCEE was purchased from Bachem (Torrance, CA, USA).  
4.3.2 Cell Culture 
Rat primary cortical astrocytes purchased from Invitrogen (Carlsbad, CA, USA), 
were isolated from the cortex of Sprague-Dawley at day E19 of gestation. Complete 
medium containing the basic nutrients as well as the supplement nutrients required for 
cellular growth was prepared by adding 15 % FBS to DMEM. Complete medium was 
always pre-warmed to 37⁰C before being used. Astrocyte cultures were prepared 
according to the protocol obtained from Invitrogen 
(http://www.lifetechnologies.com/order/catalog/product/N7745100?ICID). Briefly, cells 
were initially plated on T-25 cm2 flask at a density of 1 x 104 cells/cm2 with complete 
medium and incubated at 37⁰C, 5% CO2, and 90% humidity. When the culture was 100% 
confluent, cells were expanded and transferred onto an uncoated tissue-culture treated 
24-well plate at a seeding density of 2x104 cells/cm2 with complete medium and 
incubated at 37⁰C, 5% CO2, and 90% humidity until the culture was 100% confluent.  
4.3.3 Measurement of cell viability 
The MTT assay was performed in triplicate on 24-well plates to determine the 
cytotoxicity levels and incubation times of GCEE and tBHP as well as the cell viability 
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under tBHP-mediated cytotoxic conditions in the presence of GCEE by measuring the 
number of living cells. The reagents required for MTT assay were prepared according to 
the protocol obtained from Invitrogen 
(https://www.lifetechnologies.com/order/catalog/product/V13154?ICID). Briefly, a 12 
mM MTT stock solution was prepared in PBS and a SDS solution was prepared in 0.01 M 
HCl. To determine the cytotoxicity of GCEE, astrocytes were treated with vehicle, 750 
µM GCEE, or 900 µM GCEE in serum-free DMEM and incubated for 30 min or 60 min at 
37⁰C, 5% CO2, and 90% humidity. To determine cytotoxicity of tBHP, astrocytes were 
treated with vehicle, 100 µM tBHP, or 200 µM tBHP in serum-free DMEM and incubated 
for 30 min or 60 min at 37⁰C, 5% CO2, and 90% humidity. To determine the effects of 
GCEE on decreased cell viability due to tBHP-mediated cytotoxicity, astrocytes were 
treated with 0 µM, 750 µM or 900 µM GCEE for 60 min prior to exposure of 200 µM 
tBHP for 60 min at 37⁰C, 5% CO2, and 90% humidity. Upon the completion of each 
experiment, the medium containing different conditions of treatment was removed. The 
cells were then loaded with 250 µl of HBSS and 25 µl of 12 mM MTT, which was then 
incubated at 37⁰C, 5% CO2, and 90% humidity for 4 hours. After the 4 hour incubation, 
250 µl of the SDS-HCl solution was added to each well and incubated for an additional 4 
hours at 37⁰C, 5% CO2, and 90% humidity. The formazan levels were measured by 
reading the absorbance at 570 nm, using a microplate reader (Epoch, BioTeck, Winooski, 
VT, USA). The levels of formazan were directly proportional to the number of living cells.  
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4.3.4 Measurement of intracellular ROS formation  
The DCF assay was used to determine the ability GCEE to attenuate tBHP-
mediated intracellular oxidative stress in primary cortical astrocytes by measuring 
intracellular ROS levels on a 24-well plate. The DCF assay was performed in triplicate for 
each group. Before experiments, HBSS and DPBS were pre-warmed to 37⁰C. Once cells 
were 100 % confluent, the experiment was performed. Spent complete medium was 
removed. The cells were washed with 500 µl 1X DPBS per well and used 1X DPBS was 
rapidly removed from the wells. The cells were then incubated with 500 µl HBSS 
containing 10 µM H2DCFDA per well for 30 min at 37⁰C, 5% CO2, and 90% humidity. 
After 30 min, H2DCFDA-containing HBSS was removed and the cells were washed with 
500 µl 1X DPBS per well. After removing 1X DPBS, the cells were loaded with 500 µl 
HBSS alone or pre-treated with 500 µl HBSS containing 750 µM GCEE per well for 1 h at 
37⁰C, 5% CO2, and 90% humidity. After 1 hour, HBSS and GCEE-containing HBSS was 
removed from all wells and the cells were washed with 500 µl 1X DPBS per well. After 
removing 1X DPBS, 500 µl HBSS alone or 500 µl HBSS containing 200 µM tBHP was 
added to the cells in each well and incubated for 30 min or 60 min at 37⁰C, 5% CO2, and 
90% humidity. After addition of 200 µM tBHP (at 30 or 60 minutes), the levels of 
fluorescence were measured by using a fluorescence plate reader (GENios, TECAN, 
Männedorf, Switzerland) with at excitation at 488 nm and emission at 525 nm. The 
levels of fluorescence were directly related to the status of intracellular oxidative stress.  
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4.3.5 Statistical Analysis  
All data were analyzed using ANOVA and expressed as mean ± SD. Statistical 
significance was set at p < 0.05.  
4.4 Results 
4.4.1 Cytotoxicity of GCEE on cortical astrocytes 
The cytotoxicity of GCEE on cortical astrocytes was determined by MTT assay. 
Rat primary cortical astrocytes were incubated with different concentrations of GCEE (0, 
750, and 900 µM) for 30 min or 60 min, and the number of living cells in the different 
groups was measured. Treatment with 750 µM GCEE for 30 min increased the viability 
of astrocytes, whereas treatment with 750 µM GCEE for 60 min decreased the viability 
of astrocytes (Fig.4.1). Treatment of cortical neurons with 900 µM GCEE for 30 min as 
well as for 60 min increased the viability of astrocytes (Fig.4.1). However, the 
differences were not statistically significant compared to controls. Thus, concentrations 
(750 µM and 900 µM) and incubation times (30 min and 60 min) of GCEE were found to 
be non-toxic to astrocytes. 
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Fig.4.1 Cytotoxicity of GCEE on cortical astrocytes. Astrocytes were treated with vehicle or 
varying concentrations of GCEE (0 µM, 750 µM, 900 µM) during different incubation times (0 
min or 60 min). Cell viability was measured by MTT assay.  
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4.4.2 Cytotoxicity of tBHP on cortical astrocytes  
The cytotoxicity of TBHP on cortical astrocytes was also tested by MTT assay. Rat 
primary cortical astrocytes were exposed to different concentrations of tBHP (0, 100, 
and 200 µM) for 30 min or 60 min, and the number of living cells in the different groups 
was measured by MTT assay. The results showed that exposure of cortical astrocytes to 
tBHP (100, and 200 µM) for 30 min increased viabilities of astrocytes compared to 
control although differences were not statistically significant (Fig.4.2). In contrast, when 
astrocytes were exposed to tBHP (100, and 200 µM) for 60 min, a dose dependent 
decrease in the cell viabilities was observed (Fig.4.2). Specifically, incubation with 200 
µM tBHP for 60 min significantly decreased the number of viable cells by 33% compared 
to that of control (Fig.4.2). Thus, 200 µM tBHP at 60 min was selected as the cytotoxic 
level, while the rest of conditions were considered non-toxic levels to cortical astrocytes 
for following experiments in this study. 
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Fig.4.2 Cytotoxicity of tBHP on cortical astrocytes. Astrocytes were exposed to vehicle or 
various concentrations of tBHP (0 µM, 100 µM, and 200 µM) during different incubation times 
(30 min or 60 min), and cell viability was measured by MTT assay. (*p<0.05 compared to the 
control) 
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4.4.3 GCEE attenuates tBHP-induced oxidative stress in cortical astrocytes  
DCF assay was used to investigate the ability of GCEE to attenuate oxidative 
stress in cortical astrocytes. The levels of fluorescence were directly proportional to 
intracellular oxidative stress status. Rat primary cortical astrocytes were pre-treated 
with 750 µM GCEE for 1 hour and exposed to oxidative stress by adding 200 µM tBHP 
for 30 min. Exposure of cortical astrocytes to 200 µM tBHP alone for 30 min increased 
fluorescence levels greater than control groups, which were not statistically significant 
(Fig.4.3). In contrast, treatment with 750 µM GCEE 1 hour prior to addition of 200 µM 
tBHP for 30 min significantly decreased fluorescence levels by 35% than untreated 
astrocytes (Fig.4.3). The concentrations and incubation times of tBHP and GCEE selected 
for this experiment were found to be non-toxic to cortical astrocytes in this study 
(Fig.4.2). Hence, the reason why oxidative stress was not significantly increased in 
astrocytes after addition of tBHP in this study may be because astrocytes’ intrinsic 
property of rapidly clearing tBHP through the glutathione system according to the study 
conducted by Dringen (Dringen, Kussmaul, and Hamprecht 1998). Taken together, this 
data suggested that GCEE was able to enter into astrocytes and attenuate oxidative 
stress by enhancing the endogenous glutathione system as GSH precursor.  
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Fig.4.3 Levels of intracellular oxidative stress in cortical astrocytes exposed to non-cytotoxic 
tBHP and treated with GCEE. Astrocytes were treated with vehicle or 750 µM GCEE prior to 
exposure to vehicle or 200 µM tBHP for 30 min, and intracellular fluorescence levels were 
measured by DCF assay. (*p<0.05 compared to the control). 
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4.4.4 GCEE protects cortical astrocytes against tBHP-mediated cytotoxicity 
The ability of GCEE to protect cells from oxidative stress-related cytotoxicity was 
investigated by measuring the number of living cells via MTT assay. Rat primary cortical 
astrocytes were pre-treated with different concentrations of GCEE (0, 750 and 900 µM) 
for 60 min, followed by incubation with 200 µM tBHP for 60 min. The concentration and 
incubation time of tBHP was selected because addition of 200 µM tBHP for 60 min 
significantly decreased cell viability (Fig.4.4). Exposure of cortical astrocytes to 200 µM 
tBHP for 60 min significantly reduced the number of viable cells by 21% compared to 
control groups, consistent with the result of MTT assay with tBHP alone in this study 
(Fig.4.4). However, cortical astrocytes that were treated with GCEE (750 and 900 µM) 
for 60 min prior to addition of 200 µM tBHP showed a dose dependent increase in cell 
viability (Fig.4.4).  
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tBHP (200 µM) 
 
Fig.4.4 Viability of cortical astrocytes treated with GCEE against tBHP-mediated death. 
Astrocytes were treated with vehicle or various concentrations of GCEE (750 µM and 900 µM) 
for 1 h prior to addition of 200 µM tBHP for 60 min. Cell viability was measured by MTT assay. 
(*p<0.05 compared to the control).  
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4.4.5 GCEE attenuates oxidative stress in cortical astrocytes during tBHP-mediated 
cytotoxicity  
 
Similarly, the antioxidant capability of GCEE to reduce intracellular oxidative 
stress was investigated, but cortical astrocytes were under tBHP-induced cytotoxicity, 
whose concentration and incubation times were determined by MTT assay in this study 
(Fig.4.2). Rat primary cortical astrocytes were pre-treated with 750 µM GCEE for 1 hour 
and exposed to oxidative stress by adding 200 µM tBHP for 60 min. Exposure of cortical 
astrocytes to 200 µM tBHP alone for 60 min significantly decreased fluorescent levels by 
35% than control groups (Fig.4.5), which may be due to the decreased number of viable 
astrocytes expressing fluorescent levels as addition of 200 µM tBHP for 60 min 
significantly reduced cell viability in the previous experiment (Fig.4.2 and Fig.4.4). In 
contrast, treatment with 750 µM GCEE for 1 hour significantly decreased fluorescent 
levels by 24% compared to untreated cortical astrocytes (Fig.4.5) although treatment 
with GCEE increased the number of viable astrocytes in a dose-dependent manner 
which was significantly reduced after addition of 200 µM tBHP for 60 min (Fig.4.4). Since 
the fluorescence level obtained from DCF assay is related to the status of oxidative 
stress in intracellular space, these results showed treatment with GCEE significantly 
decreased oxidative stress in in vitro in astrocytes even during cytotoxic conditions.  
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Fig.4.5 Levels of intracellular oxidative stress in cortical astrocytes exposed to cytotoxic tBHP 
and treated with GCEE. Astrocytes were treated with vehicle or 750 µM GCEE prior to exposure 
to vehicle or 200 µM tBHP for 60 min, and intracellular fluorescence levels were measured by 
DCF assay. (*p<0.05 compared to the control) 
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4.5 Discussion 
The important roles of astrocytes in traumatic brain injury for neuroprotection 
have been investigated in TBI-models through histochemical studies. Both degenerating 
astrocytes and neurons are detected following TBI; however, the loss of astrocytes 
appears first, and prolonged neurodegeneration occurs later, which suggests that the 
loss of astrocytes contribute to neurodegeneration (Zhao et al. 2003). It has been 
confirmed by another study that the presence of astrocytes prevents the loss of brain 
tissue and protects neurons from damage, whereas the absence of astrocytes 
significantly increases the loss of brain tissue with increased number of degenerating 
neurons and inflammation (Myer et al. 2006).  
Although GCEE has shown beneficial effects on neurons, this may be the first 
study to investigate the roles of GCEE in astrocytes. In this study, we tested whether 
GCEE could increase glutathione levels in astrocytes and could protect astrocytes 
against oxidative stress and cytotoxicity in which tBHP was used to induce oxidative 
stress. Addition of tBHP increased cytotoxicity in cortical astrocytes in time- and dose- 
dependent manner. In contrast, treatment of cortical astrocytes with GCEE restored cell 
viability and decreased tBHP-mediated intracellular oxidative stress levels in astrocytes. 
Taken together, these results suggest that GCEE can enter cortical astrocytes and 
increase glutathione levels, which in turn, attenuate intracellular oxidative stress and 
protects cortical astrocytes from oxidative stress-related cytotoxicity.  
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Our finding, the ability of GCEE to increase intracellular glutathione levels in 
astrocytes, is particularly important for neuroprotection because although the presence 
of astrocytes enhances the ability of neurons to defend themselves against oxidative 
stress and promotes neuronal survival during oxidative stress, GSH depleted astrocytes 
lose their neuroprotective roles, which causes neuronal toxicity and consequently 
decreases cell viability (Drukarch et al. 1997, Drukarch et al. 1998, Chen et al. 2001, 
Pizzurro, Dao, and Costa 2014). In addition, the depletion of glutathione in astrocytes is 
also harmful to the astrocytes themselves (Im, Paik, and Han 2006). Astrocytes 
contribute to other functions of the brain besides supporting neurons. They remove 
debris in extracellular space and form the blood-brain barrier which prevents large 
molecules or foreign toxic substances from entering  the brain (He and Sun 2007). In 
other words, the loss of astrocytes results in not only neurodegeneration, but also 
overall brain dysfunction (Seifert, Schilling, and Steinhauser 2006). Thus, maintenance of 
astrocytes glutathione is crucial in protecting neurons against oxidative stress because 
astrocytic GSH plays an important role in maintenance of neuronal glutathione levels as 
well as to prevent brain dysfunction by protecting astrocytes themselves.   
In conclusion, this study has shown that GCEE can decrease oxidative stress in 
astrocytes and protect astrocytes from oxidative stress-mediated cytotoxicity due to its 
ability to increase cellular glutathione levels. Astrocytes have shown neuroprotective 
roles during oxidative stress by supplying GSH precursors to neurons. Thus, the 
beneficial effects of GCEE on astrocytes may enhance the endogenous ability of 
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astrocytes to protect neurons against oxidative stress by increasing the availability of 
GSH precursors, which would contribute to the neuroprotective effects of GCEE in TBI.  
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CHAPTER 5 
TIME COURSE ANALYSIS OF GAMMA-GLUTAMYLCYSTEINE ETHYL ESTER                          
ON ATTENUATION OF TERT-BUTYL HYDROPEROXIDE MEDIATED-OXIDATIVE STRESS             
IN VITRO IN CORTICAL NEURONS AND ASTROCYTES 
 
5.1 Overview 
Traumatic brain injury has been well documented to accompany oxidative stress 
in the brain as an early event by immediately elevating cellular reactive oxygen species 
and reactive nitrogen species levels. Oxidative stress causes deleterious cellular damage 
due to a rapid reaction between free radicals and cellular molecules, which 
consequently attributes to cellular death. Glutathione plays an important role in the 
maintenance of intracellular redox homeostasis by scavenging oxidants. Gamma-
glutamylcysteine ethyl ester has been found to increase intracellular glutathione levels 
in the brain. In this study, we assessed the effects of GCEE on combating oxidative stress 
both in neurons and astrocytes in a time dependent manner. We prepared rat primary 
cortical neurons and rat primary cortical astrocytes separately. Cells were exposed to 
oxidative stress for 30 minutes by adding tert-butyl hydroperoxide and a change in the 
levels of oxidative stress was measured by dichlorofluorescein assay. At the early point 
of oxidative stress, treatment with GCEE significantly decreased intracellular oxidative 
stress both in neurons and astrocytes. As oxidative stress proceeded, while GCEE-
treated neurons gradually increased in oxidative stress as indexed by tBHP levels, GCEE-
treated astrocytes maintained lowered intracellular oxidative stress. These results 
suggest GCEE can up-regulate glutathione both in neurons and astrocytes and attenuate 
69 
 
oxidative stress; however up-regulated neuronal glutathione by GCEE is not maintained, 
whereas up-regulated astrocytic glutathione by GCEE is maintained. Since astrocyte 
glutathione has been known to contribute to neuronal glutathione in vivo, the beneficial 
effects of GCEE in astrocytes may keep neurons from losing up-regulated glutathione by 
GCEE in vivo, which could prevent neurodegeneration in traumatic brain injury.  
5.2 Introduction 
The brain is composed of different types of cells, such as neurons and glial cells. 
Each type of cell has unique functions and further interacts with each other. Neurons, 
the most important cells in the brain, are responsible for playing a major role in 
learning, memory, emotions, and perception. The main role of glial cells is to support 
surrounding neurons. In particular, astrocytes, the most abundant glial cells, play an 
important role in protecting neurons against oxidative stress through several ways: 1)  
preventing glutamate-mediated neurotoxicity by regulating extracellular glutamate 
concentrations and 2) supplying glutathione precursors to neurons by the γ-glutamyl 
cycle, and 3) releasing neuroprotective factors in extracellular space during oxidative 
stress (Dringen, Kranich, and Hamprecht 1997, Dringen, Pfeiffer, and Hamprecht 1999, 
Dringen, Gutterer, and Hirrlinger 2000, Chen et al. 2001, Volterra et al. 1994). As 
oxidative stress is a major underlying cause of neurodegeneration, neuroprotective 
properties of astrocytes are critical to keep neurons from losing their functions, and 
ultimately preventing delayed neurodegeneration.      
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Traumatic brain injury is a sudden incident, producing physical damage to the 
exterior of the brain. The levels of reactive oxygen and nitrogen species are 
subsequently elevated following traumatic brain injury, which exceed the capability of 
the endogenous glutathione, and thereby both neurons and astrocytes are susceptible 
to oxidative stress during the brain injury. However, as the functions differ between 
neurons and astrocytes, their resistance to oxidative stress differ as astrocytes are more 
resistant to oxidative stress than neurons (Makar et al. 1994). It may be because 
neurons and astrocytes have different concentrations of glutathione, 2.5mM and 
3.8mM respectively (Raps et al. 1989). Therefore, it is crucial to boost neuronal 
glutathione levels post brain injury in order to enhance the capability of neurons to 
defend against oxidants and prevent oxidative stress-related neurodegeneration in 
which astrocyte glutathione plays an essential role through γ-glutamyl cycle. In other 
words, up-regulation of glutathione in astrocytes is also important as much as increasing 
neuronal glutathione for neuroprotection.     
Although the ability of GCEE to enrich cellular glutathione in neurons and 
astrocytes has been proven by others and by our work in Chapter 4 (Fig.4.3), 
respectively, this may be the first study investigate the antioxidant capability of GCEE to 
attenuate oxidative stress by preventing intracellular reactive oxygen and nitrogen 
species formation in a time dependent manner. In this study, we prepared rat primary 
cortical neuronal cultures and astrocytic cultures separately prepared and tert-butyl 
hydroperoxide was added into neuronal and astrocytic cultures to induce oxidative 
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stress. It has been known that oxidative stress induced by tBHP can be attenuated by 
glutathione system only in both neurons and astrocytes (Abe and Saito 1998). In other 
words, addition of tBHP leads to a rapid depletion of cellular glutathione (Rush and 
Alberts 1986, O'Connor et al. 1995). Dichlorofluorescein assay was adapted to measure 
intracellular oxidative stress level over time. The levels of fluorescence were related to 
the levels of intracellular oxidative stress.   
5.3 Materials and Procedures 
5.3.1 Materials 
All reagents required for culturing neurons and astrocytes, such as Neurobasal 
Medium, 200 mM GLUTAMAX, 50X B27 supplement, Dulbecco’s Modified Eagle Medium 
(DMEM), Fetal Bovine Serum (FBS), and Accutase were purchased from Invitrogen 
(Carlsbad, CA, USA). All reagents required for experiments, such as Dulbecco’s 
Phosphate Buffered Saline (D-PBS; without Ca2+, Mg2+, and phenol red) and Hank’s 
Balanced Salt Solution (HBSS) were also purchased from Invitrogen (Carlsbad, CA, USA). 
Both H2DCFDA (2,7-dichlorodihydrofluorescein diacetate) and tBHP (tert-butyl 
hydroperoxide) were purchased from Acros Organics. GCEE was purchased from 
Bachem (Torrance, CA, USA).  
5.3.2 Neuronal Cell Culture 
Rat primary cortical neurons purchased from Invitrogen (Carlsbad, CA, USA), 
were known to be isolated from day 18 Fisher-344 rat embryos. Complete medium used 
for culturing neurons was prepared by adding 2% of B27 supplement and 0.5 mM of 
72 
 
GLUTAMAX to Neurobasal Medium. Before culturing, complete medium was pre-
warmed to 37⁰C. Neuronal cultures were prepared according to the protocol obtained 
from Invitrogen 
(https://www.lifetechnologies.com/order/catalog/product/A1084002?ICID). Briefly, 
cells were plated on poly-D-lysine coated 48 well-plate at a density of 1 x 105 cells/well 
with complete Neurobasal medium supplemented with B27 and GLUTAMAX, and 
incubated at 37⁰C, 5% CO2, and 90% humidity. After a 24 h incubation, half of complete 
medium was aspirated from each well and the same amount of fresh complete medium 
was added. Afterwards, spent medium was replaced with fresh complete medium every 
third day until cells were ready for use.    
5.3.3 Glial Cell Culture 
Rat primary cortical astrocytes purchased from Invitrogen (Carlsbad, CA, USA), 
were known to be isolated from the cortex of Sprague-Dawley at day E19 of gestation. 
Complete medium for astrocyte cultures was prepared by adding 15% FBS to DMEM 
(high glucose). Before culturing, complete medium was pre-warmed to 37⁰C. Astrocyte 
cultures were prepared according to the protocol obtained from Invitrogen 
(https://www.lifetechnologies.com/order/catalog/product/N7745100?ICID). Briefly, 
cells were initially plated on T-25 cm2 flask at a density of 1 x 104 cells/cm2 with DMEM 
(high glucose) complete medium and expanded at 37⁰C, 5% CO2, and 90% humidity. 
When the culture was 100% confluent, cells were transferred onto an uncoated tissue-
culture treated 24-well plate at a seeding density of 2x104 cells/cm2 with DMEM 
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complete medium and incubated at 37⁰C, 5% CO2, and 90% humidity until the culture 
was 100% confluent.  
5.3.4 Measurement of intracellular ROS/RNS formation  
The ability of GCEE to prevent formation of intracellular ROS/RNS and eliminate 
increased ROS in cortical neurons was determined through DCF assay by measuring 
overall oxidative stress status. The DCF assay was conducted on primary cortical 
neurons and astrocytes separately, but applied concentrations and incubation times 
were the same. The experiment was performed at least in triplicate for each treatment. 
Before experiments began, HBSS and DPBS were pre-warmed to 37⁰C. Spent complete 
medium was removed. The cells were washed with 500 µl 1X DPBS per well and used 1X 
DPBS was rapidly removed from wells. The cells were then loaded with 500 µl HBSS 
alone or pre-treated with 500 µl HBSS containing 900 µM GCEE per well for 1 h at 37⁰C, 
5% CO2, and 90% humidity. After 1 hour, HBSS and GCEE-containing HBSS solutions were 
removed from all the wells and the cells were washed with 500 µl 1X DPBS per well. 
After removing 1X DPBS, the cells were incubated with 500 µl HBSS containing 10 µM 
H2DCFDA per well for 30 min at 37⁰C, 5% CO2, and 90% humidity. After 30 min, 
H2DCFDA-containing HBSS was removed and the cells were washed with 500 µl 1X DPBS 
per well. After removing 1X DPBS, 500 µl HBSS alone or 500 µl HBSS containing 100 µM 
tBHP was added to the cells in each well. Five minutes after addition of tBHP, the levels 
of fluorescence were measured by using a fluorescence microplate reader with 
excitation and emission wavelengths set to 488 nm and to 525 nm, respectively. 
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Intracellular ROS formations were recorded at 2.5 minutes intervals for 30 min 
(neurons) and at 1.5 min intervals for 30 min (astrocytes). 
5.3.5 Statistical Analysis  
All data were analyzed using ANOVA and expressed as mean ± SD. Statistical 
significance was set at p < 0.05.  
5.4 Results 
5.4.1 Antioxidant effects of GCEE on tBHP-induced oxidative stress in cortical neurons 
Rat primary cortical neurons were pre-treated with vehicle or 900 µM GCEE        
1 hour prior to addition of 100 µM tBHP, and a change in the levels of intracellular 
oxidative stress was observed. Addition of tBHP alone to cortical neurons initially 
decreased intracellular oxidative stress level compared to control neurons; however, the 
level of decreased intracellular oxidative stress was progressively increased and 
approximately 20 minutes after addition of tBHP, intracellular oxidative stress level 
began to exceed that of control neurons (Fig.5.1). Treatment with GCEE for 1 hour prior 
to addition of tBHP also initially decreased intracellular oxidative stress level, which was 
lower compared to untreated neurons and lasted for approximately 17 to 22 minutes 
after addition of tBHP; however, the level of intracellular oxidative stress began to 
progressively increase and exceed that of untreated neurons (Fig.5.1). Since tBHP-
induced oxidative stress can be reduced by the glutathione system, initially decreased 
oxidative stress levels indicated that naturally occurring neuronal glutathione effectively 
eliminated tBHP-induced radicals at the early point of oxidative stress and GCEE was 
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able to augment its endogenous glutathione ability as a glutathione precursor. However, 
progressively increased intracellular oxidative stress levels suggest that the effects of 
glutathione were not maintained in neurons.   
 
 
 
Fig.5.1 Levels of temporal intracellular oxidative stress in GCEE-treated cortical neurons. 
Cortical neurons were pre-treated with either vehicle or 900 µM GCEE for 1 h and exposed to 
vehicle or 100 µM tBHP. The intracellular fluorescence levels were measured 5 min after 
addition of tBHP by DCF assay at 2.5 min intervals for 30 min.   
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5.4.2 Antioxidant effects of GCEE on tBHP-induced oxidative stress in cortical 
astrocytes 
 
Rat primary cortical astrocytes were also pre-treated with vehicle or 900 µM 
GCEE for 1 hour before adding 100 µM tBHP, and a change in intracellular oxidative 
stress levels was observed. Exposure of cortical astrocytes to 100 µM tBHP alone, which 
was found not to decrease viability of astrocytes from Chapter 4 (Fig.4.2), immediately 
increased intracellular oxidative stress level compared to control astrocytes, which 
lasted throughout 30 minutes (Fig.5.2). Although it has been well known that astrocytes 
have a higher concentration of glutathione than neurons, the reason why astrocytes 
were not able to effectively decrease oxidative stress compared to neurons (Fig.5.1) 
may be because astrocytes are more dependent on the activity of catalase than 
neurons, but tBHP inhibits the activity of catalase (Abe and Saito 1998). However, as 
oxidative stress was not significantly increased, this data suggested that naturally 
occurring astrocytic glutathione was still able to defend against tBHP-mediate radicals. 
Treatment of cortical astrocytes with 900 µM GCEE for 1 hour, which was found to 
slightly increase viability of astrocytes from Chapter 4 (Fig.4.1), significantly reduced 
intracellular oxidative stress level compared to untreated astrocytes as early as 5 
minutes after addition of tBHP (Fig.5.2). Similarly, in normal conditions, treatment with 
GCEE still significantly decreased intracellular oxidative stress level compared to control 
astrocytes (Fig.5.2). Although decreased intracellular oxidative stress level began to 
progressively increase, it reached a plateau at half of the baseline level at approximately 
35 minutes. Levels were lower than that of untreated astrocytes (Fig.5.2). This data 
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supports the hypothesis that the ability of GCEE to attenuate oxidative stress in cortical 
astrocytes, which had been already shown in Chapter 4 (Fig.4.3), could be maintained 
over time.  
 
 
Fig.5.2 Levels of temporal intracellular oxidative stress in GCEE-treated cortical astrocytes. 
Cortical astrocytes were pre-treated with either vehicle or 900 µM GCEE for 1 h and exposed to 
vehicle or 100 µM tBHP. The intracellular fluorescence levels were measured 5 min after 
addition of tBHP by DCF assay at 1.5 min interval for 30 min(*p<0.05 compared to the control) 
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5.5 Discussion 
5.5.1 The effects of GCEE on neurons  
As soon as neurons were exposed to tBHP, neurons initially decreased overall 
intracellular oxidative stress levels below the baseline (Fig.5.1), indicating that 
endogenous glutathione rapidly removes tBHP-mediated radicals independent of the 
absence of catalase. Treatment with GCEE further decreased intracellular oxidative 
stress levels compared to neurons treated with tBHP alone (Fig.5.1), showing that GCEE 
can up-regulate neuronal glutathione levels and remove tBHP-induced radicals. 
However, as oxidative stress continued, oxidative stress gradually increased in both 
GCEE treated and untreated neurons, indicating that both endogenous GSH and 
exogenous GSH levels decreased. Altogether, this result suggests that GCEE can increase 
neuronal glutathione and attenuate oxidative stress, but up-regulated-GSH by GCEE is 
not maintained, but decreased within neurons.  
Neuronal GSH is affected by astrocyte GSH through gamma-glutamyl cycle which 
is initiated when astrocytes release glutathione into extracellular and provide GSH 
precursors (Walz 1989, Sagara, Makino, and Bannai 1996, Dringen, Gutterer, and 
Hirrlinger 2000, Sagara, Miura, and Bannai 1993). Numerous studies have shown that 
astrocyte-mediated neurons increase glutathione levels and decrease ROS/RNS levels, 
thereby increasing cell viability, whereas neurons alone decrease glutathione and 
increase ROS, leading to an increase in cell death (Rathinam et al. 2012, Pizzurro, Dao, 
and Costa 2014, Chen et al. 2001). Thus, increased oxidative stress in neurons in this 
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study may be due to the absence of astrocytes, especially astrocyte glutathione, which 
has been demonstrated by others (Drukarch et al. 1998, Drukarch et al. 1997, Gegg, 
Clark, and Heales 2005). 
5.5.2 The effects of GCEE on astrocytes 
As soon as astrocytes were exposed to tBHP, oxidative stress was initially 
increased. Over time, the initially increased oxidative stress remained constant; 
however, initially increased oxidative stress was not significantly different from base 
levels (Fig.5.2), indicating that astrocytes were resistant to tBHP-induced oxidative 
stress due to glutathione, which is consistent to Dringen’s work in which astrocytes 
rapidly remove tBHP through endogenous GSH system (Dringen, Kussmaul, and 
Hamprecht 1998). Moreover, it has been suggested that transcriptional up-regulation of 
γ-GC, an enzyme required for glutathione synthesis in astrocytes, can boost intracellular 
GSH levels and increase the resistance of astrocytes against oxidative stress (Iwata-
Ichikawa et al. 1999).     
Treatment with GCEE significantly decreased oxidative stress compared to non-
treated astrocytes (Fig.5.2), indicating that GCEE can effectively up-regulate GSH in 
astrocytes and such up-regulated GSH can actively reduce oxidative stress, which is 
consistent with the results observed in Chapter 4 (Fig.4.3). Furthermore, the data from 
this study showed that such decreased oxidative stress was remained at constant levels 
over the time (Fig.5.2), indicating that up-regulation of GSH by GCEE was not reduced as 
oxidative stress proceeded. These results suggest that the GCEE can constantly enhance 
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the resistance of astrocytes against oxidative stress through glutathione. These 
beneficial effects of GCEE in increasing astrocyte GSH may be beneficial for neurons 
because GSH released from astrocytes is essential to protecting neurons against 
oxidative stress (Shih et al. 2003, Chen et al. 2001).  
In conclusion, increasing neuronal glutathione is important to prevent oxidative 
stress following TBI because neurons are more vulnerable to oxidative stress (Raps et al. 
1989, Makar et al. 1994). However, increasing astrocyte glutathione is also important 
for the maintenance of neuronal glutathione because astrocytes release glutathione 
into extracellular space which supply glutathione precursors to neurons and protect 
neurons against oxidative stress (Desagher, Glowinski, and Premont 1996, Mena et al. 
1996). This study has shown that GCEE can increase cellular glutathione both in neurons 
and astrocytes, which, in turn, decreases oxidative stress. Astrocytes, not neurons, can 
maintain up-regulated GSH by GCEE. Altogether, the results from this study suggest that 
the beneficial effects of GCEE in astrocytes may enhance the beneficial effects of GCEE 
in neurons, which could ultimately prevent neurodegeneration and support GCEE as a 
potential therapeutic agent against traumatic brain injury. 
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CHAPTER 6 
CONCLUSIONS AND FUTURE STUDIES 
 
6.1 Conclusions 
Oxidative stress is an early event in traumatic brain injury. It can cause acute or 
delayed neurodegeneration following TBI. Therefore, it is important to immediately 
combat oxidative stress by using neuroprotective measures. Glutathione, a naturally 
occurring antioxidant, plays an important role in scavenging reactive oxygen species and 
reactive nitrogen species in the brain. Gamma-glutamylcysteine has been shown to 
increase cellular glutathione levels in the brain. In this thesis, we investigated the 
antioxidant capabilities of GCEE to reduce oxidative stress and protect cells against 
oxidative stress-induced degeneration as a GSH precursor.  
The goal of the first study was to test our hypothesis that GCEE could decrease 
the quantity of degenerating neurons in the brain due to its ability to increase 
glutathione and decrease the index of oxidative stress as described in other studies 
(Reed et al. 2009, Lok et al. 2011). In this study, controlled cortical impact (CCI) was 
utilized to simulate moderate TBI on rat brains and Fluoro-Jade B (FJB) was adapted to 
stain degenerating neurons on the brain tissue. We have found that there is a protective 
role of GCEE in TBI-induced neurodegeneration. Administration of GCEE post-TBI 
decreased the distributions and concentrations of degenerating neurons on the brains 
compared to untreated rat brain. This protective effect of GCEE on neurons may prevent 
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the loss of neurons and reduce the acceleration of neurodegenerative disorders during 
TBI.  
The goal of second experiment was to test whether GCEE could enter astrocytes 
and protect these structures from oxidative stress and oxidative stress-induced 
cytotoxicity. Primary cortical astrocytes were cultured and tert-butyl hydroperoxide 
(tBHP) was selected to induce oxidative stress to cell culture. DCF and MTT assays were 
conducted to measure intracellular redox status and cell viability, respectively. 
Treatment with GCEE was able to decrease tBHP-induced oxidative stress and by 
increasing GSH and such antioxidant capability of GCEE was able to protect astrocytes 
from tBHP-induced death. This protective effect of GCEE on cortical astrocytes may 
enhance neuroprotective properties of astrocytes and ultimately protect neurons during 
oxidative stress.  
The goal of the last study was to assess time course effects of GCEE on different 
types of cells: neurons and astrocytes. Primary cortical neurons and astrocytes were 
separately cultured from embryonic rats. As performed in another study, tBHP was 
added to cell cultures in order to induce oxidative stress after pre-treatment with GCEE. 
The changes in the intracellular oxidative stress levels were then measured by DCF 
assay. We have found the effects of GCEE on astrocytes last longer, but the effects of 
GCEE on neurons alone decrease over time. GCEE was able to significantly reduce 
oxidative stress up to 30 min in astrocytes, whereas GCEE was able to reduce oxidative 
stress for only 20 min. This may be because astrocytes contain higher concentrations of 
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glutathione than neurons (Raps et al. 1989). Neuronal decrease in intracellular GSH 
makes them more vulnerable to oxidative stress in the absence of astrocytes (Rathinam 
et al. 2012, Gegg, Clark, and Heales 2005, Drukarch et al. 1997). Therefore, co-culture of 
neurons with astrocytes could protect neurons and also enhance the protective effects 
of GCEE on neurons with support of protective effects of GCEE on astrocytes.  
Collectively, this work has shown that GCEE is capable of protecting both 
neurons and astrocytes against oxidative stress induced degeneration. These findings 
support the potential therapeutic roles of GCEE as neuroprotective agent in TBI.   
6.2 Future Studies 
1. (Re-analysis) In our in vivo experiment, the total number of degenerating neurons 
was quantified. In the future, spatial analysis can be tested to compare the effects of 
GCEE on ipsilateral (same side as impact) versus contralateral because degenerating 
neurons have been observed not only in the ipsilateral hemisphere, but also in the 
contralateral hemisphere although the contralateral hemisphere did not receive 
direct mechanical force during the brain injury (Hall et al. 2005). Additionally, the 
effects of GCEE on specific brain regions, particularly the hippocampus which is 
directly responsible for memory, can be investigated because degenerating neurons 
have been detected other brain regions in TBI-induced rats by others (Anderson et 
al. 2005, Zhou et al. 2012, Gao et al. 2008).      
2. The early loss of astrocytes after TBI has been observed on the brain tissue through 
histochemical study (Zhao et al. 2003). In our in vitro study, GCEE protected cortical 
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astrocytes from oxidative stress and increased cell viability. Therefore, an in vivo 
experiment should be conducted to investigate whether administration of GCEE 
after TBI could protect astrocytes and decrease the quantity of degenerating 
astrocytes through histochemical methods, as we previously identified degenerating 
neurons in our animal experiment using FJB staining techniques. For identification of  
astrocytes, glial fibrillary acidic protein which is mainly expressed on astrocytes can 
be used as a marker (Eng 1985). Protecting astrocytes would be important because 
the loss of astrocytes contribute to increasing neurodegeneration, whereas the 
presence of activated astrocytes protects neurons from degeneration following 
traumatic brain injury (Zhao et al. 2003, Myer et al. 2006).  
3. In our in vitro study, the ability of GCEE to decrease tBHP-induced oxidative stress in 
cortical astrocytes cultures lasted the time course. In contrast, the ability of GCEE to 
combat tBHP-induced intracellular oxidative stress was gradually decreased in 
cortical neuronal cultures as the exposure time increased. It has been demonstrated 
in numerous studies that neurons are vulnerable to oxidative stress in the absence 
of astrocytes due to decreased glutathione levels, whereas astrocyte-mediated 
neurons are resistant to oxidative stress due to the neuroprotective role of 
astrocytes through the glutathione system (Rathinam et al. 2012, Pizzurro, Dao, and 
Costa 2014). Therefore, this experiment can be repeated with a co-culture system of 
neurons and astrocytes to investigate whether astrocytes prevent GCEE-treated 
neurons from increasing oxidative stress, but instead enhance neuroprotective 
effects of GCEE on neurons. Levels of intracellular GSH and extracellular GSH can be 
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also measured both in neurons and astrocytes during co-culture system to 
investigate whether increased glutathione levels in astrocytes by GCEE 
administration could increase intracellular GSH in neurons based on the fact that 
astrocytes supply GSH precursors to neurons (Dringen, Gutterer, and Hirrlinger 
2000, Wang and Cynader 2000).  
4. Although GCEE was able to decrease intracellular oxidative stress in astrocytes, 
intracellular glutathione levels were not measured. Therefore, measurement of 
intracellular glutathione levels is necessary. Also, extracellular glutathione level is 
another important key factor because extracellular GSH is used as neuronal GSH 
precursors. If GCEE can either increase extracellular glutathione levels by up-
regulating intracellular GSH so that more GSH is released or GCEE itself is cleaved 
and utilized by neurons, both ways can have the potential for showing 
neuroprotective effects on neurons.    
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Table 3.1b Average number of degenerating neurons stained by FJB on rat brain tissues 
(Supporting data) 
Groups 
 
Numbers of FJB positive neurons 
(in 0.02 mm²)  
(n=3) 1 2 3 
GCEE 30 
0 0 20 
  16 
  18 
GCEE 60 
27 18 17 
14 23 26 
 18 21 
 16  
Saline 30 
0 16 14 
 23  
 14  
 30  
 30  
Saline 60 
0 21 25 
 26 22 
 34  
 32  
 26  
Sham 
0 41 2 
  7 
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Table 4.1b Cytotoxicity of GCEE on cortical astrocytes (Supporting data) 
30 min 60 min 
 Control 
GCEE 
750 µM 
GCEE 
900 µM 
 Control 
GCEE 
750 µM 
GCEE 
900 µM 
A 0.073 0.086 0.084 A 0.091 0.085 0.094 
B 0.086 0.092 0.094 B 0.097 0.092 0.117 
C 0.087 0.093 0.091 C 0.094 0.09 
0. 
087 
Blank 0.035 0.036 0.036 Blank 0.036 0.036 0.036 
 
N 3 3 3 N 3 3 3 
Mean 0.082 0.090 0.090 Mean 0.094 0.089 0.099 
Std. 
Deviation 
0.0078 0.0038 0.0051 
Std. 
Deviation 
0.0030 0.0036 0.0157 
Std. Error 
of Mean 
0.0045 0.0022 0.0030 
Std. Error 
of Mean 
0.0017 0.0021 0.0091 
% 
Control 
100 116 114 % Control 100 91 109 
 
T test P value T test P value 
Control vs GCEE 750 µM 0.17 Control vs GCEE 750 µM 0.14 
Control vs GCEE 900 µM 0.23 Control vs GCEE 900 µM 0.59 
GCEE 750 µM vs GCEE 900 µM 0.87 
GCEE 750 µM vs GCEE 900 
µM 
0.33 
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Table 4.2b Cytotoxicity of tBHP on cortical astrocytes (Supporting data) 
30 min 60 min 
 Control 
tBHP 
100 µM 
tBHP 
200 µM 
 Control 
tBHP  
100 µM 
tBHP  
200 µM 
A 0.073 0.08 0.079 A 0.091 0.091 0.073 
B 0.086 0.098 0.089 B 0.097 0.094 0.079 
C 0.087 0.094 0.092 C 0.094 0.09 0.079 
Blank 0.035 0.04 0.038 Blank 0.036 0.037 0.038 
 
N 3 3 3 N 3 3 3 
Mean 0.082 0.091 0.087 Mean 0.094 0.092 0.077 
Std. 
Deviation 
0.0078 0.0095 0.0068 
Std. 
Deviation 
0.0030 0.0021 0.0035 
Std. Error 
of Mean 
0.0045 0.0055 0.0039 
Std. Error 
of Mean 
0.0017 0.0012 0.0020 
% Control 
100 108 104 
% Control 
100 94 67 
 
T test P value T test P value 
Control vs tBHP 100 µM 0.29 Control vs tBHP 100 µM 0.33 
Control vs tBHP 200 µM 0.48 Control vs tBHP 200 µM 3.02E-03 
tBHP 100 µM vs tBHP 200 µM 0.58 
tBHP 100 µM vs tBHP 200 
µM 
3.27E-03 
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Table 4.3b Levels of intracellular oxidative stress in cortical astrocytes exposed to non-
cytotoxic tBHP and treated with GCEE (Supporting Data) 
 Control tBHP 200 µM 
tBHP 200µM 
GCEE 750µM 
C1 31851 33573 33795 41510 26823 25767 
C1 29789 39003 38627 33091 34266 30761 
C1 39725 46667 44133 39081 34384 32056 
B1 10504 8951 9204 9502 12193 11551 
 
Treatment Mean N Std. Deviation 
Std. Error of 
Mean 
% of 
Control 
Control 27041 6 6726.1 2745.9 100 
tBHP 200µM 29020 6 4322.8 1764.8 107 
tBHP 200µM  
GCEE 750µM 
18804 6 3569.0 1457.0 70 
 
T test P values 
Control vs tBHP 200 µM 5.58E-01 
tBHP 200 µM vs tBHP 200 µM + GCEE 750 µM  1.20E-03 
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Table 4.4b Viability of cortical astrocytes treated with GCEE against tBHP-mediated death 
(Supporting data) 
 C1 C2 C3 B4 B5 B6 
Control 0.131 0.129 0.143 0.043 0.043 0.042 
tBHP 200 µM 
+ GCEE 0 µM 
0.118 0.124 0.115 0.048 0.047 0.046 
tBHP 200 µM 
+ GCEE 750 µM 
0.117 0.128 0.136 0.051 0.054 0.052 
tBHP 200 µM 
+ GCEE 900 µM 
0.126 0.156 0.135 0.054 0.055 0.050 
 
 Mean N Std. Deviation 
Std. Error of 
Mean 
Control 0.134 3 0.00757 0.00437 
tBHP 200 µM 
+ GCEE 0 µM 
0.119 3 0.00458 0.00265 
tBHP 200 µM 
+ GCEE 750 µM 
0.127 3 0.00954 0.00551 
tBHP 200 µM 
+ GCEE 900 µM 
0.139 3 0.01539 0.00889 
 
T test P value 
Control vs tBHP 200 µM + GCEE 0 µM 0.0399 
Control vs tBHP 200 µM + GCEE 750 µM 0.356 
Control vs tBHP 200 µM + GCEE 900 µM 0.662 
tBHP 200 µM + GCEE 0 µM 
 vs tBHP 200 µM + GCEE 750 µM 
0.356 
tBHP 200 µM + GCEE 0 µM 
 vs tBHP 200 µM + GCEE 900 µM 
0.0972 
tBHP 200 µM + GCEE 750 µM 
 vs tBHP 200 µM + GCEE 900 µM 
0.315 
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Table 4.5b Levels of intracellular oxidative stress in cortical astrocytes exposed to cytotoxic 
tBHP and treated with GCEE (Supporting data) 
 Control Control 
tBHP  
200 µM 
tBHP  
200 µM 
GCEE 750 µM 
+tBHP 200 µM 
GCEE 750 µM 
+tBHP 200 µM 
A 26704 43724 28671 27344 26368 24653 
B 35778 47782 34150 31574 22526 26272 
C 47292 47447 28113 24991 24020 23426 
D 8740 8629 8236 7750 8086 9059 
 
 Control 
tBHP  
200 µM 
GCEE 750 µM  
+tBHP 200 µM 
N 6 6 6 
Mean 32770 21148 15972 
Std. Deviation 8581.7 3152.1 1545.5 
Std. Error of 
Mean 
3503.5 1286.8 631.00 
% of Control 100 65 49 
 
T test P value 
Control vs tBHP 200 µM 1.10E-02 
tBHP 200 vs tBHP 200 + GCEE 750 4.80E-03 
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Table 5.1b Levels of temporal intracellular oxidative stress in GCEE-treated cortical neurons 
(Supporting data) 
 Control tBHP 100 µM 
tBHP 100 µM + 
GCEE 900 µM 
tBHP 100 µM + 
GCEE 900 µM 
C1 1067 1140 1154 798 
C1 884 688 801 702 
C1 781 679 820 886 
B1 594 520 659 672 
C2 1174 1182 1121 803 
C2 962 738 871 760 
C2 880 706 859 908 
B2 662 604 672 632 
C3 1196 1265 1185 870 
C3 1018 779 926 760 
C3 958 760 886 989 
B3 691 588 666 694 
C4 1337 1321 1332 952 
C4 1106 870 1008 829 
C4 1030 830 1040 1100 
B4 781 660 719 716 
C5 1454 1466 1470 1071 
C5 1231 939 1049 883 
C5 1158 908 1098 1190 
B5 858 714 781 735 
C6 1704 1553 1617 1122 
C6 1370 1017 1172 1083 
C6 1297 1015 1224 1349 
B6 984 727 851 767 
C7 1839 1774 1756 1333 
C7 1604 1171 1339 1190 
C7 1475 1149 1400 1480 
B7 1111 847 911 784 
C8 2144 1925 1937 1438 
C8 1827 1257 1360 1360 
C8 1674 1345 1534 1585 
B8 1284 875 998 867 
C9 2305 2099 2105 1696 
C9 2004 1481 1519 1465 
C9 1926 1478 1702 1753 
B9 1471 1037 1129 936 
C10 2687 2312 2376 1885 
C10 2242 1624 1726 1720 
C10 2190 1615 1820 1948 
B10 1703 1155 1232 999 
C11 3099 2525 2577 2083 
C11 2597 1841 1868 1868 
C11 2447 1873 2134 2113 
B11 1932 1307 1350 1069 
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Table 5.1b (continued) 
 
 Control tBHP 100 µM 
tBHP 100 µM + 
GCEE 900 µM 
tBHP 100 µM + 
GCEE 900 µM 
C12 3414 2826 2953 2285 
C12 2857 2003 2021 2147 
C12 2765 2105 2388 2319 
B12 2175 1382 1484 1235 
C13 3910 3097 3163 2635 
C13 3114 2346 2224 2275 
C13 3143 2277 2595 2561 
B13 2497 1564 1667 1256 
 
 Mean Std. Deviation Std. Error of Mean 
 Control tBHP  T+G Control tBHP  T+G Control tBHP  T+G 
1 317 316 195 145 264 159 83.6 152 64.9 
2 343 271 235 152 266 115 87.6 154 47.1 
3 366 347 256 124 286 151 71.5 165 61.8 
4 377 347 326 160 273 168 92.3 157 68.5 
5 423 390 369 154 314 186 89.0 181 75.9 
6 473 468 452 217 310 183 125 179 74.6 
7 528 518 569 185 355 171 107 205 69.7 
8 598 634 603 240 363 201 138 210 82.0 
9 607 649 674 200 358 215 116 207 87.7 
10 670 695 797 273 400 242 158 231 98.8 
11 782 773 898 341 386 249 197 223 102 
12 837 929 993 351 449 303 203 259 124 
13 892 1009 1114 451 455 348 261 263 142 
 
 Relative mean P values 
 Control tBHP  tBHP + GCEE  
Control vs  
tBHP  
tBHP vs  
tBHP + GCEE  
1 1 1.00 0.61 0.996 0.409 
2 1 0.79 0.68 0.705 0.774 
3 1 0.95 0.70 0.918 0.541 
4 1 0.92 0.87 0.879 0.888 
5 1 0.92 0.87 0.879 0.898 
6 1 0.99 0.96 0.983 0.924 
7 1 0.98 1.08 0.965 0.770 
8 1 1.06 1.01 0.892 0.870 
9 1 1.07 1.11 0.869 0.896 
10 1 1.04 1.19 0.932 0.642 
11 1 0.99 1.15 0.976 0.568 
12 1 1.11 1.19 0.793 0.806 
13 1 1.13 1.25 0.767 0.710 
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Table 5.2b Levels of temporal intracellular oxidative stress in GCEE-treated cortical astrocytes 
(Supporting data) 
 Control GCEE 900 µM tBHP 100  µM tBHP 100  µM + GCEE 900  µM 
C1 6391 701 7654 7695 637 583 
C1 747 738 611 750 603 690 
C1 614 677 612 657 584 562 
B1 132 183 169 214 240 199 
C2 6535 759 7702 7746 691 628 
C2 841 838 679 843 653 743 
C2 701 767 683 733 639 613 
B2 134 188 177 225 251 206 
C3 6645 880 7758 7791 761 689 
C3 965 970 768 962 726 816 
C3 803 886 778 831 707 677 
B3 139 197 187 236 262 216 
C4 6687 1015 7859 7880 848 769 
C4 1110 1115 875 1100 810 897 
C4 925 1011 886 944 795 765 
B4 141 205 201 249 273 228 
C5 6739 1179 7997 7975 963 867 
C5 1282 1291 1004 1261 919 1011 
C5 1073 1163 1019 1082 907 872 
B5 149 218 218 266 288 243 
C6 6777 1350 8144 8145 1090 991 
C6 1473 1472 1152 1450 1047 1148 
C6 1239 1324 1173 1241 1038 995 
B6 154 241 238 289 309 262 
C7 6822 1536 8336 8309 1246 1134 
C7 1676 1677 1322 1661 1196 1300 
C7 1433 1501 1347 1421 1198 1146 
B7 162 264 263 315 334 284 
C8 6855 1722 8524 8451 1417 1292 
C8 1894 1889 1505 1898 1356 1479 
C8 1625 1683 1552 1625 1372 1309 
B8 171 289 293 345 363 311 
C9 6885 1913 8749 8692 1601 1469 
C9 2125 2094 1710 2149 1542 1666 
C9 1846 1871 1760 1840 1559 1495 
B9 183 317 327 382 398 344 
C10 6947 2107 8986 8895 1795 1664 
C10 2367 2329 1935 2422 1742 1877 
C10 2079 2068 2008 2082 1765 1702 
B10 197 349 369 424 437 379 
C11 7005 2314 9226 9098 2012 1858 
C11 2611 2548 2168 2696 1948 2095 
C11 2330 2263 2264 2340 1998 1911 
B11 214 385 409 470 477 419 
C12 7067 2498 9467 9402 2234 2066 
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Table 5.2b (continued) 
 
 Control GCEE 900 µM tBHP 100  µM tBHP 100  µM + GCEE 900  µM 
C12 2862 2793 2426 2994 2171 2316 
C12 2588 2452 2535 2603 2218 2126 
B12 231 422 456 519 526 460 
C13 7190 2694 9739 9642 2457 2278 
C13 3120 3029 2701 3297 2405 2556 
C13 2848 2657 2830 2888 2476 2346 
B13 252 462 503 569 578 500 
C14 7326 2894 10034 9906 2694 2504 
C14 3369 3279 2983 3606 2639 2792 
C14 3124 2878 3129 3193 2740 2595 
B14 269 508 555 630 635 555 
C15 7490 3094 10340 10268 2930 2739 
C15 3634 3525 3272 3923 2893 3042 
C15 3416 3087 3452 3496 2988 2818 
B15 298 551 610 690 692 611 
C16 7693 3298 10691 10516 3184 2963 
C16 3899 3798 3588 4254 3141 3292 
C16 3703 3292 3774 3800 3244 3044 
B16 324 602 666 747 754 661 
C17 7916 3521 11067 10896 3441 3231 
C17 4204 4070 3904 4601 3401 3538 
C17 4033 3511 4102 4123 3543 3267 
B17 354 656 725 815 819 721 
C18 8141 3736 11398 11207 3699 3474 
C18 4471 4368 4232 4936 3643 3804 
C18 4322 3746 4443 4448 3830 3558 
B18 381 706 786 880 884 778 
C19 8391 3951 11755 11544 3979 3729 
C19 4755 4656 4589 5298 3932 4086 
C19 4661 3988 4796 4763 4100 3790 
B19 415 761 851 943 957 836 
C20 8622 4191 12144 11918 4268 4001 
C20 5062 4965 4924 5649 4203 4349 
C20 5005 4217 5179 5126 4413 4074 
B20 448 820 911 1018 1025 896 
C21 8894 4405 12553 12296 4532 4246 
C21 5353 5256 5282 6014 4476 4623 
C21 5314 4479 5548 5482 4677 4322 
B21 481 880 976 1086 1094 963 
 
 Mean Std. Deviation 
 Control GCEE tBHP T+G Control GCEE tBHP T+G 
1 2452 522 2805 390 3298 31 3624 53 
2 2558 600 2863 433 3329 43 3610 54 
3 2665 715 2937 490 3327 50 3584 57 
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Table 5.2b (continued) 
 
 Mean Std. Deviation 
 Control GCEE tBHP T+G Control GCEE tBHP T+G 
4 2766 842 3032 564 3275 59 3573 55 
5 2882 993 3148 658 3213 70 3561 58 
6 3009 1141 3287 766 3132 79 3559 62 
7 3148 1307 3444 894 3044 93 3557 63 
8 3287 1476 3607 1034 2945 109 3536 70 
9 3436 1642 3796 1184 2832 119 3543 72 
10 3601 1819 3992 1350 2731 141 3530 77 
11 3768 1990 4193 1522 2622 152 3513 83 
12 3941 2159 4417 1696 2511 185 3513 86 
13 4134 2331 4647 1860 2432 205 3497 104 
14 4337 2509 4883 2066 2358 227 3487 99 
15 4549 2684 5142 2250 2292 251 3501 104 
16 4774 2861 5397 2437 2249 290 3492 113 
17 5030 3045 5679 2634 2194 320 3518 116 
18 5264 3244 5944 2837 2163 362 3512 124 
19 5521 3437 6227 3040 2127 397 3513 133 
20 5782 3638 6526 3258 2072 440 3525 135 
21 6039 3833 6832 3451 2056 471 3542 143 
 
Relative mean P values 
 Control GCEE  tBHP  T+G  
Control vs 
GCEE  
Control vs 
tBHP  
tBHP vs  
T+G 
1 1 0.2130 1.1440 0.1592 0.368 0.892 0.134 
2 1 0.2345 1.1192 0.1691 0.366 0.906 0.130 
3 1 0.2683 1.1017 0.1840 0.367 0.916 0.126 
4 1 0.3044 1.0962 0.2037 0.366 0.917 0.121 
5 1 0.3445 1.0921 0.2282 0.366 0.917 0.118 
6 1 0.3792 1.0925 0.2546 0.360 0.912 0.113 
7 1 0.4152 1.0938 0.2841 0.354 0.906 0.110 
8 1 0.4489 1.0973 0.3145 0.347 0.897 0.105 
9 1 0.4780 1.1047 0.3447 0.335 0.884 0.101 
10 1 0.5052 1.1085 0.3748 0.322 0.873 0.097 
11 1 0.5281 1.1127 0.4040 0.306 0.860 0.092 
12 1 0.5478 1.1207 0.4302 0.287 0.842 0.087 
13 1 0.5639 1.1241 0.4500 0.270 0.829 0.080 
14 1 0.5785 1.1257 0.4763 0.252 0.817 0.076 
15 1 0.5901 1.1304 0.4947 0.234 0.801 0.071 
16 1 0.5992 1.1305 0.5105 0.218 0.790 0.065 
17 1 0.6053 1.1289 0.5235 0.196 0.782 0.060 
18 1 0.6163 1.1293 0.5390 0.186 0.771 0.056 
19 1 0.6226 1.1280 0.5506 0.171 0.762 0.051 
20 1 0.6292 1.1287 0.5634 0.154 0.750 0.047 
21 1 0.6347 1.1312 0.5714 0.144 0.736 0.042 
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